BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N; AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-2111. [PMID: 18156031 DOI: 10.1016/s0140-6736(07)61904-7] [Cited by in Crossref: 1677] [Cited by in F6Publishing: 625] [Article Influence: 119.8] [Reference Citation Analysis]
Number Citing Articles
1 Schmidinger M, Danesi R. Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma. Oncologist 2018;23:306-15. [PMID: 29146618 DOI: 10.1634/theoncologist.2017-0335] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
2 Iyer G, Milowsky MI, Bajorin DF. Novel strategies for treating relapsed/refractory urothelial carcinoma. Expert Rev Anticancer Ther 2010;10:1917-32. [PMID: 21110758 DOI: 10.1586/era.10.182] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
3 Zhong C, Li Y, Yang J, Jin S, Chen G, Li D, Fan X, Lin H. Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects. Front Oncol 2021;11:589680. [PMID: 33854960 DOI: 10.3389/fonc.2021.589680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Mittal K, Wood LS, Rini BI. Axitinib in Metastatic Renal Cell Carcinoma. Biol Ther 2012;2:5. [PMID: 24392298 DOI: 10.1007/s13554-012-0005-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
5 Agostara B, Carruba G, Usset A. The management of cancer in the elderly: targeted therapies in oncology. Immun Ageing 2008;5:16. [PMID: 19116012 DOI: 10.1186/1742-4933-5-16] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
6 Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG, Kolenko VM. Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies. Mol Cancer Ther 2018;17:1355-64. [PMID: 29967214 DOI: 10.1158/1535-7163.MCT-17-1299] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 18.0] [Reference Citation Analysis]
7 De Groot S, Sleijfer S, Redekop WK, Oosterwijk E, Haanen JB, Kiemeney LA, Uyl-de Groot CA. Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry. BMC Cancer 2016;16:364. [PMID: 27286871 DOI: 10.1186/s12885-016-2395-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
8 Davin JL, Ducrotté P, Houédé N. [Management of side-effects of targeted therapies in renal cancer: gastrointestinal side-effects]. Bull Cancer 2011;98:S69-78. [PMID: 25819128 DOI: 10.1684/bdc.2011.1445] [Reference Citation Analysis]
9 Kim H, Shim BY, Lee SJ, Lee JY, Lee HJ, Kim IH. Loss of Von Hippel-Lindau (VHL) Tumor Suppressor Gene Function: VHL-HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC). Int J Mol Sci 2021;22:9795. [PMID: 34575959 DOI: 10.3390/ijms22189795] [Reference Citation Analysis]
10 Autorino R, Di Lorenzo G. An evolving role for immunotherapy in metastatic RCC. Nat Rev Urol 2010;7:305-7. [PMID: 20535143 DOI: 10.1038/nrurol.2010.64] [Reference Citation Analysis]
11 Jebali M, Elaidi R, Brizard M, Fouque J, Takouchop C, Sabatier B, Oudard S, Medioni J. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma. BMC Cancer. 2017;17:27. [PMID: 28061764 DOI: 10.1186/s12885-016-2993-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
12 Jian Y, Yang K, Sun X, Zhao J, Huang K, Aldanakh A, Xu Z, Wu H, Xu Q, Zhang L, Xu C, Yang D, Wang S. Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma. Front Immunol 2021;12:639636. [PMID: 33767709 DOI: 10.3389/fimmu.2021.639636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Lee CH, Hötker AM, Voss MH, Feldman DR, Woo KM, Patil S, Coskey DT, Akin O, Hsieh JJ, Motzer RJ. Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. Clin Genitourin Cancer 2016;14:56-62. [PMID: 26404107 DOI: 10.1016/j.clgc.2015.07.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
14 Wagener N, Macher-Goeppinger S, Pritsch M, Hüsing J, Hoppe-Seyler K, Schirmacher P, Pfitzenmaier J, Haferkamp A, Hoppe-Seyler F, Hohenfellner M. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 2010;10:524. [PMID: 20920340 DOI: 10.1186/1471-2407-10-524] [Cited by in Crossref: 105] [Cited by in F6Publishing: 89] [Article Influence: 8.8] [Reference Citation Analysis]
15 Molina AM, Tickoo SK, Ishill N, Trinos MJ, Schwartz LH, Patil S, Feldman DR, Reuter VE, Russo P, Motzer RJ. Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol. 2011;34:454-459. [PMID: 21127411 DOI: 10.1097/coc.0b013e3181f47aa4] [Cited by in Crossref: 59] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
16 Ganini C, Rovereto B, Porta C. Surgery and target agents for renal cell carcinoma treatment: the path between proper interaction. Urologia 2011;78 Suppl 18:9-15. [PMID: 22081423 DOI: 10.5301/RU.2011.8769] [Reference Citation Analysis]
17 Trask PC, Bushmakin AG, Cappelleri JC, Tarazi J, Rosbrook B, Bycott P, Kim S, Stadler WM, Rini B. Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. J Cancer Surviv 2011;5:255-62. [PMID: 21476015 DOI: 10.1007/s11764-011-0178-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
18 Halabi S, Rini B, Escudier B, Stadler WM, Small EJ. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer 2014;120:52-60. [PMID: 24347384 DOI: 10.1002/cncr.28221] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
19 White NM, Masui O, Newsted D, Scorilas A, Romaschin AD, Bjarnason GA, Siu KW, Yousef GM. Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. Br J Cancer 2014;110:1250-9. [PMID: 24496460 DOI: 10.1038/bjc.2013.828] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
20 Vadakara J, Borghaei H. Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmgenomics Pers Med 2012;5:113-23. [PMID: 23226067 DOI: 10.2147/PGPM.S24258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 14] [Article Influence: 0.1] [Reference Citation Analysis]
21 Eikesdal HP, Kalluri R. Drug resistance associated with antiangiogenesis therapy. Semin Cancer Biol 2009;19:310-7. [PMID: 19524042 DOI: 10.1016/j.semcancer.2009.05.006] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
22 Hepgur M, Sadeghi S, Dorff TB, Quinn DI. Tivozanib in the treatment of renal cell carcinoma. Biologics 2013;7:139-48. [PMID: 23788831 DOI: 10.2147/BTT.S32958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.2] [Reference Citation Analysis]
23 Aeppli S, Eboulet EI, Eisen T, Escudier B, Fischer S, Larkin J, Gruenwald V, McDermott D, Oldenburg J, Omlin A, Porta C, Rini B, Schmidinger M, Sternberg C, Rothermundt C. Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. ESMO Open 2020;5:e000852. [PMID: 32669298 DOI: 10.1136/esmoopen-2020-000852] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
24 Khetani VV, Portal DE, Shah MR, Mayer T, Singer EA. Combination drug regimens for metastatic clear cell renal cell carcinoma. World J Clin Oncol 2020; 11(8): 541-562 [PMID: 32879843 DOI: 10.5306/wjco.v11.i8.541] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
25 Su Y, Yang WB, Li S, Ye ZJ, Shi HZ, Zhou Q. Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One 2012;7:e35629. [PMID: 22539986 DOI: 10.1371/journal.pone.0035629] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
26 Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, Leenders WP, van Furth WR. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 2009;9:444. [PMID: 20015387 DOI: 10.1186/1471-2407-9-444] [Cited by in Crossref: 122] [Cited by in F6Publishing: 126] [Article Influence: 9.4] [Reference Citation Analysis]
27 Kishida T, Yao M, Uemura H, Ohlmann C, Tomita Y, Bukowski RM, Naito S. Molecular genetic events associated with renal cell carninoma and its implication to treatment by molecular target therapy. Int J Urol 2010;17:198-205. [PMID: 20409215 DOI: 10.1111/j.1442-2042.2010.02455.x] [Reference Citation Analysis]
28 Hadoux J, Vignot S, De La Motte Rouge T. Renal cell carcinoma: focus on safety and efficacy of temsirolimus. Clin Med Insights Oncol 2010;4:143-54. [PMID: 21234295 DOI: 10.4137/CMO.S4482] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
29 Santoni M, Heng DY, Bracarda S, Procopio G, Milella M, Porta C, Matrana MR, Cartenì G, Crabb SJ, De Giorgi U, Basso U, Masini C, Calabrò F, Vitale MG, Santini D, Massari F, Galli L, Fornarini G, Ricotta R, Buti S, Zucali P, Caffo O, Morelli F, Carrozza F, Martignetti A, Gelibter A, Iacovelli R, Mosca A, Atzori F, Vau N, Incorvaia L, Ortega C, Scarpelli M, Lopez-Beltran A, Cheng L, Paolucci V, Graham J, Pierce E, Scagliarini S, Sepe P, Verzoni E, Merler S, Rizzo M, Sorgentoni G, Conti A, Piva F, Cimadamore A, Montironi R, Battelli N. Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. Cancers (Basel) 2019;12:E84. [PMID: 31905816 DOI: 10.3390/cancers12010084] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
30 Najjar YG, Rini BI. Novel agents in renal carcinoma: a reality check. Ther Adv Med Oncol 2012;4:183-94. [PMID: 22754592 DOI: 10.1177/1758834012443725] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
31 Tsao CK, Liaw B, He C, Galsky MD, Sfakianos J, Oh WK. Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol 2017;9:287-98. [PMID: 28491148 DOI: 10.1177/1758834016687261] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
32 Yin C, Ma G, Rong Y, Kong P, Yang Q, Jiang C, Liao F, Zhang B, He W, Xia L. The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer. J Cancer 2016;7:1901-6. [PMID: 27698931 DOI: 10.7150/jca.15802] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
33 Rodriguez-Vida A, Hutson TE, Bellmunt J, Strijbos MH. New treatment options for metastatic renal cell carcinoma. ESMO Open 2017;2:e000185. [PMID: 28761748 DOI: 10.1136/esmoopen-2017-000185] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 8.4] [Reference Citation Analysis]
34 Rajan A, Kim C, Heery CR, Guha U, Gulley JL. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother 2016;12:2219-31. [PMID: 27135835 DOI: 10.1080/21645515.2016.1175694] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
35 Zhang H, Huang Z, Zou X, Liu T. Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials. Oncotarget 2016;7:82473-81. [PMID: 27756883 DOI: 10.18632/oncotarget.12666] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
36 Molina AM, Jia X, Feldman DR, Hsieh JJ, Ginsberg MS, Velasco S, Patil S, Motzer RJ. Long-term response to sunitinib therapy for metastatic renal cell carcinoma. Clin Genitourin Cancer 2013;11:297-302. [PMID: 23707221 DOI: 10.1016/j.clgc.2013.04.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
37 Fangusaro J, Gururangan S, Poussaint TY, McLendon RE, Onar-Thomas A, Warren KE, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, Boyett JM, Kun LE, Fouladi M. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). Cancer 2013;119:4180-7. [PMID: 24104527 DOI: 10.1002/cncr.28343] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
38 Morishita A, Gong J, Masaki T. Targeting receptor tyrosine kinases in gastric cancer. World J Gastroenterol 2014; 20(16): 4536-4545 [PMID: 24782606 DOI: 10.3748/wjg.v20.i16.4536] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
39 Clark PE. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int. 2009;76:939-945. [PMID: 19657325 DOI: 10.1038/ki.2009.296] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 4.9] [Reference Citation Analysis]
40 Clark PE. Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma. Biologics 2010;4:187-97. [PMID: 20714356 DOI: 10.2147/btt.s7818] [Reference Citation Analysis]
41 Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, Heath E, Quinn DI, Gandara DR. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology 2010;76:923-6. [PMID: 20646741 DOI: 10.1016/j.urology.2010.04.025] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 5.3] [Reference Citation Analysis]
42 Di Salvatore M, Lo Giudice L, Rossi E, Santonocito C, Nazzicone G, Rodriquenz MG, Cappuccio S, Inno A, Fuso P, Orlandi A, Strippoli A, Capoluongo E, Astone A, Cassano A, Barone C. Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis. Clin Transl Oncol 2016;18:40-6. [PMID: 26141413 DOI: 10.1007/s12094-015-1334-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
43 Narayanan S, Srinivas S. Incorporating VEGF-targeted therapy in advanced urothelial cancer. Ther Adv Med Oncol 2017;9:33-45. [PMID: 28203296 DOI: 10.1177/1758834016667179] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
44 Bukowski RM. Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer. Curr Oncol Rep 2009;11:81-3. [PMID: 19216838 DOI: 10.1007/s11912-009-0013-7] [Reference Citation Analysis]
45 Verman R, Lara PN. Cytokines in the Management of Advanced Renal Cell Cancer. In: Lara PN, Jonasch E, editors. Kidney Cancer. Cham: Springer International Publishing; 2015. pp. 245-58. [DOI: 10.1007/978-3-319-17903-2_15] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
46 Lee LS, Tan M. Predictive models for the practical management of renal cell carcinoma. Nat Rev Urol 2012;9:73-84. [DOI: 10.1038/nrurol.2011.224] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
47 Patel JN, Jiang C, Hertz DL, Mulkey FA, Owzar K, Halabi S, Ratain MJ, Friedman PN, Small EJ, Carducci MA, Mahoney JF, Kelley MJ, Morris MJ, Kelly WK, McLeod HL. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer 2015;121:1025-31. [PMID: 25417775 DOI: 10.1002/cncr.29169] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
48 Eisenbeis AM, Grau SJ. Monoclonal antibodies and Fc fragments for treating solid tumors. Biologics 2012;6:13-20. [PMID: 22291463 DOI: 10.2147/BTT.S19955] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
49 Li P, Wong YN, Armstrong K, Haas N, Subedi P, Davis-Cerone M, Doshi JA. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras. Cancer Med 2016;5:169-81. [PMID: 26645975 DOI: 10.1002/cam4.574] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
50 Kawabata H, Ohishi T, Suzuki H, Asano T, Kawada M, Suzuki H, Kaneko MK, Kato Y. A Defucosylated Mouse Anti-CD10 Monoclonal Antibody (31-mG2a-f) Exerts Antitumor Activity in a Mouse Xenograft Model of Renal Cell Cancers. Monoclon Antib Immunodiagn Immunother 2022. [PMID: 35483055 DOI: 10.1089/mab.2021.0049] [Reference Citation Analysis]
51 Abu-Hejleh T, Mezhir JJ, Goodheart MJ, Halfdanarson TR. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep. 2012;14:277-284. [PMID: 22532266 DOI: 10.1007/s11912-012-0238-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
52 Smolensky D, Rathore K, Cekanova M. Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer. Drug Des Devel Ther 2016;10:3305-22. [PMID: 27784990 DOI: 10.2147/DDDT.S112113] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
53 Odia Y, Shih JH, Kreisl TN, Fine HA. Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort. J Neurooncol 2014;120:431-40. [PMID: 25098701 DOI: 10.1007/s11060-014-1571-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
54 Boige V, Malka D, Bourredjem A, Dromain C, Baey C, Jacques N, Pignon JP, Vimond N, Bouvet-Forteau N, De Baere T, Ducreux M, Farace F. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist. 2012;17:1063-1072. [PMID: 22707516 DOI: 10.1634/theoncologist.2011-0465] [Cited by in Crossref: 66] [Cited by in F6Publishing: 54] [Article Influence: 6.6] [Reference Citation Analysis]
55 Sleeman J, Steeg PS. Cancer metastasis as a therapeutic target. Eur J Cancer 2010;46:1177-80. [PMID: 20307970 DOI: 10.1016/j.ejca.2010.02.039] [Cited by in Crossref: 125] [Cited by in F6Publishing: 122] [Article Influence: 10.4] [Reference Citation Analysis]
56 Grépin R, Guyot M, Dumond A, Durivault J, Ambrosetti D, Roussel JF, Dupré F, Quintens H, Pagès G. The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor. Theranostics 2020;10:1107-21. [PMID: 31938054 DOI: 10.7150/thno.38346] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
57 Ding Z, German P, Bai S, Feng Z, Gao M, Si W, Sobieski MM, Stephan CC, Mills GB, Jonasch E. Agents that stabilize mutated von Hippel-Lindau (VHL) protein: results of a high-throughput screen to identify compounds that modulate VHL proteostasis. J Biomol Screen 2012;17:572-80. [PMID: 22357874 DOI: 10.1177/1087057112436557] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
58 Vaishampayan U. Landmark Trials in Renal Cancer. KCA 2018;2:11-21. [DOI: 10.3233/kca-170026] [Reference Citation Analysis]
59 Duncan MJ, Patte KA, Leatherdale ST. Hit the chronic… physical activity: are cannabis associated mental health changes in adolescents attenuated by remaining active? Soc Psychiatry Psychiatr Epidemiol 2021;56:141-52. [PMID: 33150455 DOI: 10.1007/s00127-020-01900-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Johannsen M, Stoll C, Raida M, van Oorschot B, Flörcken A. Supportive therapy and complementary medicine in renal cell carcinoma. World J Urol 2021. [PMID: 34821959 DOI: 10.1007/s00345-021-03885-1] [Reference Citation Analysis]
61 Delea TE, Khuu A, Heng DY, Haas T, Soulières D. Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma. Br J Cancer 2012;107:1059-68. [PMID: 22935581 DOI: 10.1038/bjc.2012.367] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
62 Puente J, García Del Muro X, Pinto Á, Láinez N, Esteban E, Arranz JÁ, Gallardo E, Méndez MJ, Maroto P, Grande E, Suárez C. Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations. Target Oncol 2016;11:129-41. [PMID: 26706236 DOI: 10.1007/s11523-015-0408-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
63 Cortés-Funes H. The role of antiangiogenesis therapy: bevacizumab and beyond. Clin Transl Oncol 2009;11:349-55. [PMID: 19531449 DOI: 10.1007/s12094-009-0368-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
64 Khan Y, Slattery TD, Pickering LM. Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma. Cancers (Basel) 2020;12:E3750. [PMID: 33322163 DOI: 10.3390/cancers12123750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Kim HS, Kim JH, Jang HJ, Han B, Zang DY. Clinicopathologic Significance of VHL Gene Alteration in Clear-Cell Renal Cell Carcinoma: An Updated Meta-Analysis and Review. Int J Mol Sci 2018;19:E2529. [PMID: 30149673 DOI: 10.3390/ijms19092529] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
66 Tolnay E, Ghimessy ÁK, Juhász E, Sztancsik Z, Losonczy G, Dombi P, Vennes Z, Helf L, Csada E, Sárosi V. The efficacy and safety of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer: Final results of AVALANCHE, an observational cohort study. Oncol Lett 2019;17:1750-60. [PMID: 30675234 DOI: 10.3892/ol.2018.9766] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
67 Zurita AJ, Jonasch E, Wu HK, Tran HT, Heymach JV. Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. Cancer. 2009;115:2346-2354. [PMID: 19402074 DOI: 10.1002/cncr.24228] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
68 Yuasa T, Masuda H, Yamamoto S, Numao N, Yonese J. Biomarkers to predict prognosis and response to checkpoint inhibitors. Int J Clin Oncol 2017;22:629-34. [PMID: 28382562 DOI: 10.1007/s10147-017-1122-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
69 de Groot S, Redekop WK, Versteegh MM, Sleijfer S, Oosterwijk E, Kiemeney LALM, Uyl-de Groot CA. Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma. Qual Life Res 2018;27:115-24. [PMID: 28917029 DOI: 10.1007/s11136-017-1704-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
70 Xu J, Pham CG, Albanese SK, Dong Y, Oyama T, Lee CH, Rodrik-Outmezguine V, Yao Z, Han S, Chen D, Parton DL, Chodera JD, Rosen N, Cheng EH, Hsieh JJ. Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. J Clin Invest 2016;126:3526-40. [PMID: 27482884 DOI: 10.1172/JCI86120] [Cited by in Crossref: 55] [Cited by in F6Publishing: 43] [Article Influence: 9.2] [Reference Citation Analysis]
71 Agarwala SS, Case S. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Oncologist 2010;15:236-45. [PMID: 20215359 DOI: 10.1634/theoncologist.2009-0141] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 3.9] [Reference Citation Analysis]
72 Fisher R, Larkin J. Individualising treatment choices in a crowded treatment algorithm. EJC Suppl 2013;11:160-8. [PMID: 26217125 DOI: 10.1016/j.ejcsup.2013.07.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Tykodi SS, Sandmaier BM, Warren EH, Thompson JA. Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after. Expert Opin Biol Ther 2011;11:763-73. [PMID: 21417772 DOI: 10.1517/14712598.2011.566855] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
74 Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, James N, Oliver RT, Mardiak J, Hussain T, Sylvester R, Parmar MK, Royston P, Mulders PF. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 2010;375:641-8. [PMID: 20153039 DOI: 10.1016/S0140-6736(09)61921-8] [Cited by in Crossref: 81] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
75 Ayllon J, Pignot G. Risque hémorragique et anti-angiogéniques. Progrès en Urologie 2010;20:S20-2. [DOI: 10.1016/s1166-7087(10)70020-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
76 León L, García-Figueiras R, Suárez C, Arjonilla A, Puente J, Vargas B, Méndez Vidal MJ, Sebastiá C. Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer. Target Oncol 2014;9:9-24. [PMID: 24338498 DOI: 10.1007/s11523-013-0304-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
77 Belibi FA, Edelstein CL. Metastatic Renal Cancer: What Role for Everolimus? Clin Med Rev Oncol 2010;2:4. [PMID: 24771995 DOI: 10.4137/CMRO.S1551] [Reference Citation Analysis]
78 Wiechno P, Kucharz J, Sadowska M, Michalski W, Sikora-Kupis B, Jonska-Gmyrek J, Poniatowska G, Nietupski K, Ossolinski K, Demkow T. Contemporary treatment of metastatic renal cell carcinoma. Med Oncol 2018;35:156. [PMID: 30368624 DOI: 10.1007/s12032-018-1217-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
79 Lai XX, Xu RA, Yu-Ping L, Yang H. Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Onco Targets Ther 2016;9:2421-8. [PMID: 27143937 DOI: 10.2147/OTT.S96156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
80 Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A, Lim L, Hutson T. Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer 2011;104:741-5. [PMID: 21266975 DOI: 10.1038/sj.bjc.6606061] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
81 Qi WX, Shen Z, Tang LN, Yao Y. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups. Eur J Clin Pharmacol. 2014;70:893-906. [PMID: 24858820 DOI: 10.1007/s00228-014-1687-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
82 Goey AK, Figg WD. Potential novel role of bevacizumab in glioblastoma and cervical cancer. Cancer Biol Ther 2014;15:1296-8. [PMID: 25046485 DOI: 10.4161/cbt.29926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
83 Rassy E, Flippot R, Albiges L. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. Ther Adv Med Oncol 2020;12:1758835920907504. [PMID: 32215057 DOI: 10.1177/1758835920907504] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 13.5] [Reference Citation Analysis]
84 Pal SK, Vanderwalde A, Hurria A, Figlin RA. Systemic therapies for metastatic renal cell carcinoma in older adults. Drugs Aging 2011;28:635-49. [PMID: 21812499 DOI: 10.2165/11592880-000000000-00000] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
85 Bazarbashi S, Alkhateeb S, Abusamra A, Rabah D, Alotaibi M, Almansour M, Murshid E, Alsharm A, Alolayan A, Ahmad I, Alghamdi K, Alghamdi A. Saudi oncology society and Saudi urology association combined clinical management guidelines for renal cell carcinoma. Urol Ann 2014;6:286-9. [PMID: 25371602 DOI: 10.4103/0974-7796.140974] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
86 Ingels A, Campi R, Capitanio U, Amparore D, Bertolo R, Carbonara U, Erdem S, Kara Ö, Klatte T, Kriegmair MC, Marchioni M, Mir MC, Ouzaïd I, Pavan N, Pecoraro A, Roussel E, de la Taille A. Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. Nat Rev Urol 2022. [PMID: 35546184 DOI: 10.1038/s41585-022-00592-3] [Reference Citation Analysis]
87 Richey SL, Ng C, Lim ZD, Jonasch E, Tannir NM. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol 2011;29:e203-5. [PMID: 21172884 DOI: 10.1200/JCO.2010.31.6091] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
88 Hah YS, Koo KC. Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review. Int J Mol Sci 2021;22:4452. [PMID: 33923219 DOI: 10.3390/ijms22094452] [Reference Citation Analysis]
89 Forde PF, Hall LJ, de Kruijf M, Bourke MG, Doddy T, Sadadcharam M, Soden DM. Non-viral immune electrogene therapy induces potent antitumour responses and has a curative effect in murine colon adenocarcinoma and melanoma cancer models. Gene Ther 2015;22:29-39. [PMID: 25373914 DOI: 10.1038/gt.2014.95] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
90 Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol. 2011;185:439-444. [PMID: 21167518 DOI: 10.1016/j.juro.2010.09.086] [Cited by in Crossref: 84] [Cited by in F6Publishing: 77] [Article Influence: 7.0] [Reference Citation Analysis]
91 Arimoto A, Uehara K, Tsuzuki T, Aiba T, Ebata T, Nagino M. Role of bevacizumab in neoadjuvant chemotherapy and its influence on microvessel density in rectal cancer. Int J Clin Oncol 2015;20:935-42. [PMID: 25788218 DOI: 10.1007/s10147-015-0818-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
92 Kachaamy T, Gupta D, Edwin P, Vashi P. Safety of endoscopy in cancer patients on antiangiogenic agents: A retrospective multicenter outcomes study. PLoS One 2017;12:e0176899. [PMID: 28472195 DOI: 10.1371/journal.pone.0176899] [Reference Citation Analysis]
93 Motzer RJ. New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overview. Oncologist 2011;16 Suppl 2:1-3. [PMID: 21346034 DOI: 10.1634/theoncologist.2011-S2-01] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
94 Chen XL, Lei YH, Liu CF, Yang QF, Zuo PY, Liu CY, Chen CZ, Liu YW. Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis. PLoS One 2013;8:e66721. [PMID: 23818962 DOI: 10.1371/journal.pone.0066721] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
95 Barresi V, Branca G, Caffo M, Caltabiano R, Ieni A, Vitarelli E, Lanzafame S, Tuccari G. Immuno-expression of endoglin and smooth muscle actin in the vessels of brain metastases. Is there a rational for anti-angiogenic therapy? Int J Mol Sci 2014;15:5663-79. [PMID: 24699047 DOI: 10.3390/ijms15045663] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
96 Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, Dubrot J, Palazon A, Hervas-Stubbs S, Gurpide A, Lopez-Picazo JM, Grande-Pulido E, Melero I, Perez-Gracia JL. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer. 2009;100:1111-1119. [PMID: 19277038 DOI: 10.1038/sj.bjc.6604965] [Cited by in Crossref: 136] [Cited by in F6Publishing: 124] [Article Influence: 10.5] [Reference Citation Analysis]
97 Heidenreich A, Finke F. [Clinical network structures in uro-oncology. A model for the future?]. Urologe A 2008;47:1128-32. [PMID: 18651123 DOI: 10.1007/s00120-008-1823-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
98 Bukowski RM. Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab. Cancer Manag Res 2010;2:83-96. [PMID: 21188099 DOI: 10.2147/cmar.s7540] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
99 Gill DM, Agarwal N, Vaishampayan U. Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma. Am Soc Clin Oncol Educ Book 2017;37:319-29. [PMID: 28561652 DOI: 10.1200/EDBK_174469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
100 Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK. State of the science: an update on renal cell carcinoma. Mol Cancer Res 2012;10:859-80. [PMID: 22638109 DOI: 10.1158/1541-7786.MCR-12-0117] [Cited by in Crossref: 100] [Cited by in F6Publishing: 74] [Article Influence: 10.0] [Reference Citation Analysis]
101 Grignol VP, Olencki T, Relekar K, Taylor C, Kibler A, Kefauver C, Wei L, Walker MJ, Chen HX, Kendra K, Carson WE 3rd. A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. J Immunother 2011;34:509-15. [PMID: 21654521 DOI: 10.1097/CJI.0b013e31821dcefd] [Cited by in Crossref: 37] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
102 Kim JH, Park I, Lee JL. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features. Cancer Chemother Pharmacol 2016;78:325-32. [DOI: 10.1007/s00280-016-3093-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
103 Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L, Tong Z, Wang S, Li J, Wang Z. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer. 2014;14:820. [PMID: 25376790 DOI: 10.1186/1471-2407-14-820] [Cited by in Crossref: 99] [Cited by in F6Publishing: 123] [Article Influence: 12.4] [Reference Citation Analysis]
104 Bergerot PG, Hahn AW, Bergerot CD, Jones J, Pal SK. The Role of Circulating Tumor DNA in Renal Cell Carcinoma. Curr Treat Options Oncol 2018;19:10. [PMID: 29464405 DOI: 10.1007/s11864-018-0530-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
105 Procopio G, Verzoni E, Iacovelli R, Biasoni D, Testa I, Porcu L, De Braud F. Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. Br J Cancer 2012;107:1227-32. [PMID: 22968651 DOI: 10.1038/bjc.2012.327] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
106 Rosa R, Damiano V, Nappi L, Formisano L, Massari F, Scarpa A, Martignoni G, Bianco R, Tortora G. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer. Br J Cancer 2013;109:686-93. [PMID: 23839492 DOI: 10.1038/bjc.2013.360] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
107 Narayan V, Keefe S, Haas N, Wang L, Puzanov I, Putt M, Catino A, Fang J, Agarwal N, Hyman D, Smith AM, Finkelman BS, Narayan HK, Ewer S, ElAmm C, Lenihan D, Ky B. Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res 2017;23:3601-9. [PMID: 28196874 DOI: 10.1158/1078-0432.CCR-16-2869] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 7.4] [Reference Citation Analysis]
108 Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30:1534-1540. [PMID: 22454414 DOI: 10.1200/JCO.2011.39.4767] [Cited by in Crossref: 313] [Cited by in F6Publishing: 191] [Article Influence: 31.3] [Reference Citation Analysis]
109 Rini BI. Lapatinib therapy for patients with advanced renal cell carcinoma. Nat Clin Pract Oncol 2008;5:626-7. [PMID: 18762792 DOI: 10.1038/ncponc1220] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
110 Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 2011;10:351-64. [PMID: 21532565 DOI: 10.1038/nrd3374] [Cited by in Crossref: 194] [Cited by in F6Publishing: 172] [Article Influence: 17.6] [Reference Citation Analysis]
111 Summers J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist 2010;15:104-11. [PMID: 20061402 DOI: 10.1634/theoncologist.2009-0250] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 5.5] [Reference Citation Analysis]
112 Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar PR. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer. 2013;108:1052-1060. [PMID: 23422754 DOI: 10.1038/bjc.2013.69] [Cited by in Crossref: 115] [Cited by in F6Publishing: 100] [Article Influence: 12.8] [Reference Citation Analysis]
113 Boegemann M, Goebell PJ, Woike M, Buncke J, Schlack K, Schrader AJ. Assessment of prognosis by established prognosis scores and physicians' judgement in mRCC patients: an analysis of the STAR-TOR registry. Transl Androl Urol 2021;10:4062-74. [PMID: 34804848 DOI: 10.21037/tau-20-938] [Reference Citation Analysis]
114 Kats-Ugurlu G, Oosterwijk E, Muselaers S, Oosterwijk-Wakka J, Hulsbergen-van de Kaa C, de Weijert M, van Krieken H, Desar I, van Herpen C, Maass C. Neoadjuvant sorafenib treatment of clear cell renal cell carcinoma and release of circulating tumor fragments. Neoplasia. 2014;16:221-228. [PMID: 24726142 DOI: 10.1016/j.neo.2014.03.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
115 Shepard DR, Cooney MM, Elson P, Bukowski RM, Dreicer R, Rini BI, Garcia JA. A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. Invest New Drugs 2012;30:364-7. [PMID: 20711630 DOI: 10.1007/s10637-010-9516-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
116 Jha PK, Vankalakunti M, Siddini V, Bonu R, Prakash GK, Babu K, Ballal HS. Sunitinib induced nephrotic syndrome and thrombotic microangiopathy. Indian J Nephrol 2013;23:67-70. [PMID: 23580811 DOI: 10.4103/0971-4065.107215] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
117 Carducci MA, Manola J, Nair SG, Liu G, Rousey S, Dutcher JP, Wilding G. Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800). Clin Genitourin Cancer 2015;13:531-539.e1. [PMID: 26272427 DOI: 10.1016/j.clgc.2015.07.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
118 Miwa S, Yamamoto N, Hayashi K, Takeuchi A, Igarashi K, Tsuchiya H. Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma. Cancers (Basel) 2020;12:E1758. [PMID: 32630642 DOI: 10.3390/cancers12071758] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
119 Jang A, Adler DM, Rauterkus GP, Bilen MA, Barata PC. Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going? Cancers (Basel) 2021;13:5065. [PMID: 34680214 DOI: 10.3390/cancers13205065] [Reference Citation Analysis]
120 Grande E, Escudier B. ESMO guidelines on renal cell carcinoma: the paradox of the fine line that separates scientific robustness from cost-efficiency analysis. Ann Oncol 2021;32:1466-7. [PMID: 34718116 DOI: 10.1016/j.annonc.2021.10.212] [Reference Citation Analysis]
121 Zhu Y, Xu L, Zhang J, Hu X, Liu Y, Yin H, Lv T, Zhang H, Liu L, An H, Liu H, Xu J, Lin Z. Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells. Cancer Sci 2013;104:1052-61. [PMID: 23578198 DOI: 10.1111/cas.12176] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
122 Sircar K, Rao P, Jonasch E, Monzon FA, Tamboli P. Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features. Chin J Cancer 2013;32:303-11. [PMID: 23237216 DOI: 10.5732/cjc.012.10136] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
123 He HL, Yao WX. A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma. Biosci Rep 2017;37:BSR20170827. [PMID: 29074560 DOI: 10.1042/BSR20170827] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
124 Pak KH, Jo A, Choi HJ, Choi Y, Kim H, Cheong JH. The different role of intratumoral and peritumoral lymphangiogenesis in gastric cancer progression and prognosis. BMC Cancer 2015;15:498. [PMID: 26141595 DOI: 10.1186/s12885-015-1501-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
125 Pili R, Carducci M, Brown P, Hurwitz H. An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer. Invest New Drugs 2014;32:1258-68. [PMID: 25152243 DOI: 10.1007/s10637-014-0147-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
126 Salgia M, Adashek J, Bergerot P, Pal SK. Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice. Kidney Cancer 2017;1:99-105. [PMID: 30334011 DOI: 10.3233/KCA-170019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
127 Lassoued W, Murphy D, Tsai J, Oueslati R, Thurston G, Lee WM. Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors. Cancer Biol Ther 2010;10:1326-33. [PMID: 21079419 DOI: 10.4161/cbt.10.12.14009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
128 Cao Y. VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs. Nat Rev Endocrinol. 2014;10:530-539. [PMID: 25048037 DOI: 10.1038/nrendo.2014.114] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 6.9] [Reference Citation Analysis]
129 Chau V, Bilusic M. Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date. Cancer Manag Res 2020;12:7321-30. [PMID: 32884346 DOI: 10.2147/CMAR.S216605] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
130 Ahn T, Roberts MJ, Abduljabar A, Joshi A, Perera M, Rhee H, Wood S, Vela I. A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC). Mol Imaging Biol 2019;21:799-807. [PMID: 30617728 DOI: 10.1007/s11307-018-01307-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
131 Umer M, Mohib Y, Atif M, Nazim M. Skeletal metastasis in renal cell carcinoma: A review. Ann Med Surg (Lond) 2018;27:9-16. [PMID: 29511536 DOI: 10.1016/j.amsu.2018.01.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
132 Tan Q, Wang W, Long Y, Chen G. Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis. Exp Ther Med 2015;9:2275-80. [PMID: 26136973 DOI: 10.3892/etm.2015.2427] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
133 Di Lorenzo G, Buonerba C. Kidney cancer: overall survival is an unsuitable primary end point. Nat Rev Urol 2010;7:367-8. [PMID: 20616795 DOI: 10.1038/nrurol.2010.84] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
134 Hess J, vom Dorp F, Becker M, Rübben H, Börgermann C. [Impact of surgery for residual tumors after chemotherapy]. Urologe A 2009;48:73-8. [PMID: 19066839 DOI: 10.1007/s00120-008-1756-8] [Reference Citation Analysis]
135 Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6:507-18. [DOI: 10.1038/nrclinonc.2009.110] [Cited by in Crossref: 257] [Cited by in F6Publishing: 224] [Article Influence: 19.8] [Reference Citation Analysis]
136 Jones TM, Carew JS, Nawrocki ST. Therapeutic Targeting of Autophagy for Renal Cell Carcinoma Therapy. Cancers (Basel) 2020;12:E1185. [PMID: 32392870 DOI: 10.3390/cancers12051185] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
137 Chung EK, Posadas EM, Kasza K, Karrison T, Manchen E, Hahn OM, Stadler WM. A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Am J Clin Oncol 2011;34:150-4. [PMID: 20395787 DOI: 10.1097/COC.0b013e3181d6b2fe] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
138 Shah JH, Nanus DM. Recent advances in management of renal cancer. F1000 Med Rep 2009;1:90. [PMID: 20948687 DOI: 10.3410/M1-90] [Reference Citation Analysis]
139 Bharthuar A, Pandey H, Sood S. Management of metastatic renal cell carcinoma - mini review. J Kidney Cancer VHL 2015;2:75-83. [PMID: 28326262 DOI: 10.15586/jkcvhl.2015.28] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
140 Guyot M, Hilmi C, Ambrosetti D, Merlano M, Lo Nigro C, Durivault J, Grépin R, Pagès G. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies. Oncotarget 2017;8:9174-88. [PMID: 27999187 DOI: 10.18632/oncotarget.13942] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
141 Finkelmeier F, You SJ, Waidmann O, Wolff R, Zeuzem S, Bähr O, Trojan J. Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis. J Gastrointest Cancer 2016;47:82-8. [PMID: 26714801 DOI: 10.1007/s12029-015-9795-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
142 Tsironis G, Liontos M, Kyriazoglou A, Koutsoukos K, Tsiara A, Kaparelou M, Zakopoulou R, Cohen A, Skafida E, Fontara S, Zagouri F, Bamias A, Dimopoulos MA. Axitinib as a third or further line of treatment in renal cancer: a single institution experience. BMC Urol 2020;20:60. [PMID: 32487200 DOI: 10.1186/s12894-020-00618-1] [Reference Citation Analysis]
143 Tsavachidou-Fenner D, Tannir N, Tamboli P, Liu W, Petillo D, Teh B, Mills GB, Jonasch E. Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Ann Oncol 2010;21:1599-606. [PMID: 20089566 DOI: 10.1093/annonc/mdp600] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
144 Motzer RJ, Escudier B, Gannon A, Figlin RA. Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. Oncologist 2017;22:41-52. [PMID: 27807302 DOI: 10.1634/theoncologist.2016-0197] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
145 Narayan V, Haas NB. Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives. Int J Nephrol Renovasc Dis 2016;9:65-72. [PMID: 27099525 DOI: 10.2147/IJNRD.S83874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
146 Totzeck M, Mincu RI, Rassaf T. Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients. J Am Heart Assoc 2017;6:e006278. [PMID: 28862931 DOI: 10.1161/JAHA.117.006278] [Cited by in Crossref: 50] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
147 Flaherty KT, Manola JB, Pins M, McDermott DF, Atkins MB, Dutcher JJ, George DJ, Margolin KA, DiPaola RS. BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804). J Clin Oncol 2015;33:2384-91. [PMID: 26077237 DOI: 10.1200/JCO.2015.60.9727] [Cited by in Crossref: 51] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
148 Bai R, Yuan C, Sun W, Zhang J, Luo Y, Gao Y, Li Y, Gong Y, Xie C. NEK2 plays an active role in Tumorigenesis and Tumor Microenvironment in Non-Small Cell Lung Cancer. Int J Biol Sci 2021;17:1995-2008. [PMID: 34131401 DOI: 10.7150/ijbs.59019] [Reference Citation Analysis]
149 Damiano V, Rosa R, Formisano L, Nappi L, Gelardi T, Marciano R, Cozzolino I, Troncone G, Agrawal S, Veneziani BM, De Placido S, Bianco R, Tortora G. Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. Br J Cancer 2013;108:1616-23. [PMID: 23571736 DOI: 10.1038/bjc.2013.153] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
150 Escudier B, Albiges L. Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma. Drugs 2011;71:1179-91. [PMID: 21711062 DOI: 10.2165/11591410-000000000-00000] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
151 Kaelin WG Jr. New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein. Ann N Y Acad Sci 2010;1210:1-7. [PMID: 20973793 DOI: 10.1111/j.1749-6632.2010.05781.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
152 Zarrabi K, Wu S. Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma. Curr Oncol Rep 2018;20:41. [PMID: 29611002 DOI: 10.1007/s11912-018-0684-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
153 An MM, Zou Z, Shen H, Liu P, Chen ML, Cao YB, Jiang YY. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol 2010;66:813-21. [PMID: 20401474 DOI: 10.1007/s00228-010-0815-4] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
154 Kramer MW, Merseburger AS, Peters I, Waalkes S, Kuczyk MA. [Systemic and surgical management of metastatic renal cell carcinoma]. Urologe A 2012;51:217-25. [PMID: 22009257 DOI: 10.1007/s00120-011-2713-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
155 McDermott DF. The application of high-dose interleukin-2 for metastatic renal cell carcinoma. Med Oncol 2009;26 Suppl 1:13-7. [PMID: 19148594 DOI: 10.1007/s12032-008-9152-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
156 Bazarbashi S, Al Othman K, Al Otaibi M, Abusamra A, Rabah D, Aljubran A, Murshid E, Al Oraifi I, El-Naghi M, Bahader Y, Soudy H, Rehman A. Saudi Oncology Society clinical management guidelines for renal cell carcinoma. Urol Ann 2011;3 Suppl:S3-5. [PMID: 21673849 DOI: 10.4103/0974-7796.78548] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
157 Cao Y, E G, Wang E, Pal K, Dutta SK, Bar-Sagi D, Mukhopadhyay D. VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res 2012;72:3912-8. [PMID: 22693250 DOI: 10.1158/0008-5472.CAN-11-4058] [Cited by in Crossref: 89] [Cited by in F6Publishing: 60] [Article Influence: 8.9] [Reference Citation Analysis]
158 Xiao H, Wang K, Li D, Wang K, Yu M. Evaluation of FGFR1 as a diagnostic biomarker for ovarian cancer using TCGA and GEO datasets. PeerJ 2021;9:e10817. [PMID: 33604191 DOI: 10.7717/peerj.10817] [Reference Citation Analysis]
159 Méjean A, Lebret T. [Targeted therapies]. Prog Urol 2008;18 Suppl 7:S228-33. [PMID: 19070797 DOI: 10.1016/S1166-7087(08)74548-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
160 Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 2009;15:6277-83. [PMID: 19773375 DOI: 10.1158/1078-0432.CCR-09-0717] [Cited by in Crossref: 68] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
161 Heng DY, Kollmannsberger C. State-of-the-art treatment of metastatic renal cell carcinoma. Curr Oncol 2009;16 Suppl 1:S16-23. [PMID: 19478897 DOI: 10.3747/co.v16i0.407] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
162 Dong M, Wang R, Sun P, Zhang D, Zhang Z, Zhang J, Tse G, Zhong L. Clinical significance of hypertension in patients with different types of cancer treated with antiangiogenic drugs. Oncol Lett 2021;21:315. [PMID: 33692847 DOI: 10.3892/ol.2021.12576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 van der Veldt AA, Boven E, Helgason HH, van Wouwe M, Berkhof J, de Gast G, Mallo H, Tillier CN, van den Eertwegh AJ, Haanen JB. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 2008;99:259-65. [PMID: 18594533 DOI: 10.1038/sj.bjc.6604456] [Cited by in Crossref: 96] [Cited by in F6Publishing: 85] [Article Influence: 6.9] [Reference Citation Analysis]
164 Bhatia S, Curti B, Ernstoff MS, Gordon M, Heath EI, Miller WH Jr, Puzanov I, Quinn DI, Flaig TW, VanVeldhuizen P, Byrnes-Blake K, Freeman JA, Bittner R, Hunder N, Souza S, Thompson JA. Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer 2014;2:2. [PMID: 24829759 DOI: 10.1186/2051-1426-2-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
165 Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010;21:1381-1389. [PMID: 20538785 DOI: 10.1681/asn.2010020167] [Cited by in Crossref: 141] [Cited by in F6Publishing: 59] [Article Influence: 11.8] [Reference Citation Analysis]
166 Kapoor A. First-line treatment options in metastatic renal cell cancer. Can Urol Assoc J 2016;10:S236-8. [PMID: 28096934 DOI: 10.5489/cuaj.4307] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
167 Saltarella I, Morabito F, Giuliani N, Terragna C, Omedè P, Palumbo A, Bringhen S, De Paoli L, Martino E, Larocca A, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Dammacco F, Boccadoro M, Vacca A, Ria R. Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. J Hematol Oncol 2019;12:4. [PMID: 30626425 DOI: 10.1186/s13045-018-0691-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
168 Longoria TC, Tewari KS. Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations. Drugs 2015;75:1853-65. [PMID: 26474780 DOI: 10.1007/s40265-015-0481-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
169 Basu B, Eisen T. Perspectives in drug development for metastatic renal cell cancer. Target Oncol 2010;5:139-56. [PMID: 20689997 DOI: 10.1007/s11523-010-0149-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
170 Chen Y, Tortorici MA, Garrett M, Hee B, Klamerus KJ, Pithavala YK. Clinical pharmacology of axitinib. Clin Pharmacokinet 2013;52:713-25. [PMID: 23677771 DOI: 10.1007/s40262-013-0068-3] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 7.0] [Reference Citation Analysis]
171 Reckamp KL, Strieter RM, Figlin RA. Chemokines as therapeutic targets in renal cell carcinoma. Expert Rev Anticancer Ther 2008;8:887-93. [PMID: 18533798 DOI: 10.1586/14737140.8.6.887] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
172 Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26:5422-5428. [PMID: 18936475 DOI: 10.1200/jco.2008.16.9847] [Cited by in Crossref: 698] [Cited by in F6Publishing: 274] [Article Influence: 49.9] [Reference Citation Analysis]
173 Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol. 2010;28:1502-1507. [PMID: 20159822 DOI: 10.1200/jco.2009.24.7759] [Cited by in Crossref: 142] [Cited by in F6Publishing: 43] [Article Influence: 11.8] [Reference Citation Analysis]
174 Barbieri CE, Chinnaiyan AM, Lerner SP, Swanton C, Rubin MA. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. Eur Urol 2017;71:237-46. [PMID: 27567210 DOI: 10.1016/j.eururo.2016.08.024] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
175 Jonasch E, Pagliaro LC, Tannir NM. Long-term management of patients with metastatic renal cell carcinoma on targeted agents. Expert Rev Anticancer Ther 2010;10:1883-9. [PMID: 21110755 DOI: 10.1586/era.10.195] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
176 Busch J, Seidel C, Weikert S, Wolff I, Kempkensteffen C, Weinkauf L, Hinz S, Magheli A, Miller K, Grünwald V. Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. BMC Cancer 2011;11:295. [PMID: 21756335 DOI: 10.1186/1471-2407-11-295] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
177 Cella D, Escudier B, Rini B, Chen C, Bhattacharyya H, Tarazi J, Rosbrook B, Kim S, Motzer R. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Br J Cancer 2013;108:1571-8. [PMID: 23579211 DOI: 10.1038/bjc.2013.145] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 4.9] [Reference Citation Analysis]
178 Ballarin R, Spaggiari M, Cautero N, De Ruvo N, Montalti R, Longo C, Pecchi A, Giacobazzi P, De Marco G, D'Amico G, Gerunda GE, Di Benedetto F. Pancreatic metastases from renal cell carcinoma: the state of the art. World J Gastroenterol 2011;17:4747-56. [PMID: 22147975 DOI: 10.3748/wjg.v17.i43.4747] [Cited by in CrossRef: 95] [Cited by in F6Publishing: 82] [Article Influence: 8.6] [Reference Citation Analysis]
179 Xu KY, Wu S. Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma. Biomark Res 2015;3:5. [PMID: 25734007 DOI: 10.1186/s40364-015-0030-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
180 O'Rourke CJ, Knabben V, Bolton E, Moran D, Lynch T, Hollywood D, Perry AS. Manipulating the epigenome for the treatment of urological malignancies. Pharmacol Ther 2013;138:185-96. [PMID: 23353098 DOI: 10.1016/j.pharmthera.2013.01.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
181 Cho DC. Therapeutic challenges in advanced renal cell carcinoma. Clin Pract (Lond) 2013;10:39-46. [PMID: 23378893 DOI: 10.2217/cpr.12.77] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
182 Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist. 2010;15:539-547. [PMID: 20511320 DOI: 10.1634/theoncologist.2009-0274] [Cited by in Crossref: 89] [Cited by in F6Publishing: 79] [Article Influence: 7.4] [Reference Citation Analysis]
183 Rodenburg RJ, Eskens F. Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives. Int J Nephrol Renovasc Dis 2019;12:137-41. [PMID: 31190952 DOI: 10.2147/IJNRD.S169056] [Reference Citation Analysis]
184 Buess M, Rajski M, Vogel-Durrer BM, Herrmann R, Rochlitz C. Tumor-endothelial interaction links the CD44(+)/CD24(-) phenotype with poor prognosis in early-stage breast cancer. Neoplasia 2009;11:987-1002. [PMID: 19794958 DOI: 10.1593/neo.09670] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
185 Lameire N. Nephrotoxicity of recent anti-cancer agents. Clin Kidney J 2014;7:11-22. [PMID: 25859345 DOI: 10.1093/ckj/sft135] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
186 Isono T, Chano T, Yonese J, Yuasa T. Therapeutic inhibition of mitochondrial function induces cell death in starvation-resistant renal cell carcinomas. Sci Rep 2016;6:25669. [PMID: 27157976 DOI: 10.1038/srep25669] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
187 Zhang HL, Sheng XN, Li XS, Wang HK, Chi ZH, He ZS, Ye DW, Guo J. Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors. BMC Cancer 2017;17:16. [PMID: 28056874 DOI: 10.1186/s12885-016-3016-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
188 Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14:141-148. [PMID: 23312463 DOI: 10.1016/s1470-2045(12)70559-4] [Cited by in Crossref: 504] [Cited by in F6Publishing: 249] [Article Influence: 56.0] [Reference Citation Analysis]
189 Gyanchandani R, Kim S. Predictive biomarkers to anti-VEGF therapy: progress toward an elusive goal. Clin Cancer Res 2013;19:755-7. [PMID: 23386694 DOI: 10.1158/1078-0432.CCR-12-3585] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
190 Schmid TA, Gore ME. Sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol 2016;8:348-71. [PMID: 27904651 DOI: 10.1177/1756287216663979] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
191 Newsome BW, Ernstoff MS. The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? Br J Clin Pharmacol 2008;66:6-19. [PMID: 18503606 DOI: 10.1111/j.1365-2125.2008.03187.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
192 Tamura R, Morimoto Y, Sato M, Hikichi T, Yoshida K, Toda M. A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma. Vaccines (Basel) 2020;8:E498. [PMID: 32887369 DOI: 10.3390/vaccines8030498] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
193 Fisher R, Larkin J, Swanton C. Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma? Front Oncol 2012;2:49. [PMID: 22655275 DOI: 10.3389/fonc.2012.00049] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
194 Porta C, Paglino C, Grünwald V. Sunitinib re-challenge in advanced renal-cell carcinoma. Br J Cancer 2014;111:1047-53. [PMID: 24800947 DOI: 10.1038/bjc.2014.214] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
195 Groenewegen G, Walraven M, Vermaat J, de Gast B, Witteveen E, Giles R, Haanen J, Voest E. Targeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma. Br J Cancer 2012;106:284-9. [PMID: 22215065 DOI: 10.1038/bjc.2011.515] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
196 Larochelle P, Kollmannsberger C, Feldman RD, Schiffrin EL, Poirier L, Patenaude F, Ruether D, Myers M, Bjarnason G. Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents. Curr Oncol 2012;19:202-8. [PMID: 22876146 DOI: 10.3747/co.19.972] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
197 Teishima J, Murata D, Inoue S, Hayashi T, Mita K, Hasegawa Y, Kato M, Kajiwara M, Shigeta M, Maruyama S, Moriyama H, Fujiwara S, Matsubara A. Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor. Curr Urol 2021;15:187-92. [PMID: 35069080 DOI: 10.1097/CU9.0000000000000042] [Reference Citation Analysis]
198 Pichler R, Horninger W, Aigner F, Heidegger I. [Bevacizumab as first-line therapy in metastatic renal cell carcinoma: Progression-free survival for 3 years]. Urologe A 2016;55:381-5. [PMID: 26471795 DOI: 10.1007/s00120-015-3976-z] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
199 Kanesvaran R, Tan MH. Targeted therapy for renal cell carcinoma: The next lap. J Carcinog 2014;13:3. [PMID: 24737951 DOI: 10.4103/1477-3163.127638] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
200 Ghosh AP, Willey CD, Anderson JC, Welaya K, Chen D, Mehta A, Ghatalia P, Madan A, Naik G, Sudarshan S, Sonpavde G. Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma. Oncotarget 2017;8:29220-32. [PMID: 28418903 DOI: 10.18632/oncotarget.16352] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
201 McKay RR, De Velasco G, Werner L, Bellmunt J, Harshman L, Sweeney C, Rosenberg JE, Hirsch M, Signoretti S, Van Allen EM, Walsh M, Vaishampayan U, McDermott DF, Choueiri TK. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer 2016;122:2389-98. [PMID: 27198170 DOI: 10.1002/cncr.30056] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
202 Wang B, Gu W, Wan F, Shi G, Ye D. Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma. Int Braz J Urol 2019;45:89-99. [PMID: 29570259 DOI: 10.1590/S1677-5538.IBJU.2017.0500] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
203 Ederhy S, Duclos B, Mahammedi H, Doublet JD. [Management of side-effects of targeted therapies in renal cancer: cardiovascular side-effects]. Bull Cancer 2011;98:S19-34. [PMID: 25819123 DOI: 10.1684/bdc.2011.1443] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
204 Grothey E, Sartor O, Bukowski R. Highlights from: The 2008 Genitourinary Cancers Symposium; February 14-16, 2008; San Francisco, CA. Clinical Genitourinary Cancer 2008;6:9-14. [DOI: 10.1016/s1558-7673(11)70045-3] [Reference Citation Analysis]
205 Khambati HK, Choueiri TK, Kollmannsberger CK, North S, Bjarnason GA, Vaishampayan UN, Wood L, Knox JJ, Tan MH, MacKenzie MJ, Donskov F, Rini BI, Heng DY; International mRCC Database Consortium. Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population. Clin Genitourin Cancer 2014;12:354-8. [PMID: 24819320 DOI: 10.1016/j.clgc.2014.02.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
206 Escudier B, Gross-goupil M. Révolutions dans l’approche thérapeutique du cancer du rein: Rationnel moléculaire et applications cliniques. Med Sci (Paris) 2008;24:697-9. [DOI: 10.1051/medsci/20082489697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
207 Morrissey KM, Yuraszeck TM, Li CC, Zhang Y, Kasichayanula S. Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities. Clin Transl Sci. 2016;9:89-104. [PMID: 26924066 DOI: 10.1111/cts.12391] [Cited by in Crossref: 104] [Cited by in F6Publishing: 96] [Article Influence: 17.3] [Reference Citation Analysis]
208 Reimann M, Folprecht G, Haase R, Trautmann K, Ehninger G, Reichmann H, Ziemssen F, Ziemssen T. Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational study. Exp Transl Stroke Med 2013;5:7. [PMID: 23668549 DOI: 10.1186/2040-7378-5-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
209 Harrison MR. Pharmacotherapy options in advanced renal cell carcinoma: what role for pazopanib? Clin Med Insights Oncol 2011;5:349-64. [PMID: 22174596 DOI: 10.4137/CMO.S6087] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
210 Zhao F, Cella D, Manola J, DiPaola RS, Wagner LI, Haas NSB. Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial. Support Care Cancer 2018;26:1889-95. [PMID: 29274030 DOI: 10.1007/s00520-017-4027-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
211 Sharma MR, Schilsky RL. Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol. 2012;9:208-214. [PMID: 22143142 DOI: 10.1038/nrclinonc.2011.190] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
212 Nathan P, Vinayan A. Imaging techniques as predictive and prognostic biomarkers in renal cell carcinoma. Ther Adv Med Oncol 2013;5:119-31. [PMID: 23450112 DOI: 10.1177/1758834012463624] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
213 Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R, Prausová J, Moiseyenko VM, van Hazel G, Cunningham D, Arnold D, Schmoll HJ, Ten Tije AJ, McKendrick J, Kröning H, Humblet Y, Grávalos C, Le-Guennec S, Andria M, Dochy E, Vishwanath RL, Macarulla T, Tabernero J. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol 2016;11:383-400. [PMID: 26706237 DOI: 10.1007/s11523-015-0402-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
214 Goi T, Nakazawa T, Hirono Y, Yamaguchi A. The anti-tumor effect is enhanced by simultaneously targeting VEGF and PROK1 in colorectal cancer. Oncotarget 2015;6:6053-61. [PMID: 25788276 DOI: 10.18632/oncotarget.3474] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
215 Ueda T, Uemura H, Tomita Y, Tsukamoto T, Kanayama H, Shinohara N, Tarazi J, Chen C, Kim S, Ozono S, Naito S, Akaza H. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Jpn J Clin Oncol 2013;43:616-28. [PMID: 23630366 DOI: 10.1093/jjco/hyt054] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 5.7] [Reference Citation Analysis]
216 Wurz GT, Kao CJ, DeGregorio MW. Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol 2016;8:4-31. [PMID: 26753003 DOI: 10.1177/1758834015615514] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
217 Heng DY, Kollmannsberger C, Chi KN. Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. Ther Adv Med Oncol 2010;2:39-49. [PMID: 21789125 DOI: 10.1177/1758834009352498] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
218 Pelant T, Larsen EH, Lund L, Borre M, Erichsen R, Nørgaard M, Jacobsen JB. Survival of patients with kidney cancer in central and northern Denmark, 1998-2009. Clin Epidemiol 2011;3 Suppl 1:53-8. [PMID: 21814471 DOI: 10.2147/CLEP.S20619] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
219 Yasuda Y, Saito K, Yuasa T, Uehara S, Kawamura N, Yokoyama M, Ishioka J, Matsuoka Y, Yamamoto S, Okuno T, Yonese J, Kihara K, Fujii Y. Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol 2017;22:1081-6. [PMID: 28733795 DOI: 10.1007/s10147-017-1166-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
220 Siebels M, Hegele A, Varga Z, Oberneder R, Doehn C, Heinzer H; Deutsche Gesellschaft für Immun- und Targeted Therapie e.V. (DGFIT). [Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies]. Urologe A 2011;50:1110-7. [PMID: 21559917 DOI: 10.1007/s00120-011-2553-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
221 Strong C, Yanamadala V, Khanna A, Walcott BP, Nahed BV, Borges LF, Coumans JV. Surgical treatment options and management strategies of metastatic renal cell carcinoma to the lumbar spinal nerve roots. J Clin Neurosci 2013;20:1546-9. [PMID: 23931936 DOI: 10.1016/j.jocn.2013.02.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
222 Bukowski RM. How I treat renal cell carcinoma. J Oncol Pract 2008;4:150-2. [PMID: 20856622 DOI: 10.1200/JOP.0838501] [Reference Citation Analysis]
223 Mazza C, Escudier B, Albiges L. Nivolumab in renal cell carcinoma: latest evidence and clinical potential. Ther Adv Med Oncol 2017;9:171-81. [PMID: 28344662 DOI: 10.1177/1758834016679942] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
224 Economopoulou P, Kotsakis A, Kapiris I, Kentepozidis N. Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res 2015;7:133-43. [PMID: 26082660 DOI: 10.2147/CMAR.S77400] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 6.1] [Reference Citation Analysis]
225 Mitchell CC, Parikh OA. Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib. Patient Prefer Adherence 2014;8:503-11. [PMID: 24790418 DOI: 10.2147/PPA.S38989] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
226 Fischer S, Gillessen S, Rothermundt C. Sequence of treatment in locally advanced and metastatic renal cell carcinoma. Transl Androl Urol 2015;4:310-25. [PMID: 26816832 DOI: 10.3978/j.issn.2223-4683.2015.04.07] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
227 Amit L, Ben-Aharon I, Vidal L, Leibovici L, Stemmer S. The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review. PLoS One 2013;8:e51780. [PMID: 23349675 DOI: 10.1371/journal.pone.0051780] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
228 Sankin A, Hakimi AA, Hsieh JJ, Molina AM. Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies. Front Oncol 2015;5:67. [PMID: 25905038 DOI: 10.3389/fonc.2015.00067] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
229 Koneru R, Hotte SJ. Role of cytokine therapy for renal cell carcinoma in the era of targeted agents. Curr Oncol 2009;16 Suppl 1:S40-4. [PMID: 19478896 DOI: 10.3747/co.v16i0.417] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
230 Wang ZP, Zhang HF, Zhang F, Hu BL, Wei HT, Guo YY. Bevacizumab did not reduce the risk of anemia associated with chemotherapy: an up-to-date meta-analysis. Eur J Clin Pharmacol 2015;71:517-24. [PMID: 25845654 DOI: 10.1007/s00228-015-1818-y] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
231 Nguyen DP, Vilaseca A, Vertosick EA, Corradi RB, Touijer KA, Benfante NE, Sjoberg DD, Russo P. Histologic subtype impacts cancer-specific survival in patients with sarcomatoid-variant renal cell carcinoma treated surgically. World J Urol 2016;34:539-44. [PMID: 26215750 DOI: 10.1007/s00345-015-1644-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
232 Huang H, Zheng Y, Zhu J, Zhang J, Chen H, Chen X. An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients. PLoS One 2014;9:e89960. [PMID: 24599121 DOI: 10.1371/journal.pone.0089960] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
233 Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 2020;77:1745-70. [PMID: 31690961 DOI: 10.1007/s00018-019-03351-7] [Cited by in Crossref: 157] [Cited by in F6Publishing: 151] [Article Influence: 52.3] [Reference Citation Analysis]
234 Considine B, Hurwitz ME. Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma. Curr Oncol Rep 2019;21:34. [PMID: 30848378 DOI: 10.1007/s11912-019-0779-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
235 Park K, Lee JL, Ahn JH, Lee KH, Jeong IG, Song C, Hong B, Hong JH, Ahn H. Efficacy and safety of everolimus in korean patients with metastatic renal cell carcinoma following treatment failure with a vascular endothelial growth factor receptor-tyrosine kinase inhibitor. Cancer Res Treat 2014;46:339-47. [PMID: 25036572 DOI: 10.4143/crt.2013.154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
236 Barni S, Cabiddu M, Guarneri P, Lonati V, Petrelli F. The risk for anemia with targeted therapies for solid tumors. Oncologist 2012;17:715-24. [PMID: 22531357 DOI: 10.1634/theoncologist.2012-0024] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
237 Papavassilis P, Krabbe LM, Thielen B, Bögemann M, Moritz R, Hoffmeister I, Hertle L, Herrmann E. [Systemic treatment of metastatic renal cell carcinoma: change of paradigms after introduction of targeted therapy]. Urologe A 2014;53:531-6. [PMID: 24549799 DOI: 10.1007/s00120-013-3408-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
238 Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Tannir NM, Jonasch E. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol 2014;191:611-8. [PMID: 24018239 DOI: 10.1016/j.juro.2013.08.090] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 8.7] [Reference Citation Analysis]
239 Eskander RN, Randall LM. Bevacizumab in the treatment of ovarian cancer. Biologics 2011;5:1-5. [PMID: 21383911 DOI: 10.2147/BTT.S13071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 15] [Article Influence: 0.2] [Reference Citation Analysis]
240 Herrmann E, Bierer S, Wülfing C. Update on systemic therapies of metastatic renal cell carcinoma. World J Urol 2010;28:303-9. [PMID: 20180125 DOI: 10.1007/s00345-010-0519-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
241 Melisi D, Frizziero M, Tamburrino A, Zanotto M, Carbone C, Piro G, Tortora G. Toll-Like Receptor 9 Agonists for Cancer Therapy. Biomedicines 2014;2:211-28. [PMID: 28548068 DOI: 10.3390/biomedicines2030211] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
242 Walz JM, Boehringer D, Deissler HL, Faerber L, Goepfert JC, Heiduschka P, Kleeberger SM, Klettner A, Krohne TU, Schneiderhan-Marra N, Ziemssen F, Stahl A. Pre-Analytical Parameters Affecting Vascular Endothelial Growth Factor Measurement in Plasma: Identifying Confounders. PLoS One 2016;11:e0145375. [PMID: 26730574 DOI: 10.1371/journal.pone.0145375] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
243 Feinberg BA, Jolly P, Wang ST, Fortner B, Scott J, Gilmore J, Neary MP, Duh MS. Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. Med Oncol 2012;29:786-94. [PMID: 21479699 DOI: 10.1007/s12032-011-9922-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
244 Malik L, Parsons H, Mahalingam D, Ehler B, Goros M, Mejia A, Brenner A, Sarantopoulos J. Clinical outcomes and survival of advanced renal cancer patients in phase I clinical trials. Clin Genitourin Cancer 2014;12:359-65. [PMID: 24582088 DOI: 10.1016/j.clgc.2014.01.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
245 Yang K, Wang YJ, Chen XR, Chen HN. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig 2010;30:229-41. [PMID: 20225906 DOI: 10.2165/11532260-000000000-00000] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
246 Jewett M, Finelli A, Kollmannsberger C, Wood L, Legere L, Basiuk J, Canil C, Heng D, Reaume N, Tanguay S, Atkins M, Bjarnason G, Dancey J, Evans M, Fleshner N, Haider M, Kapoor A, Uzzo R, Maskens D, Soulieres D, Yousef G, Basappa N, Bendali N, Black P, Blais N, Cagiannos I, Care M, Chow R, Chung H, Czaykowski P, Derosa D, Durrant K, Ellard S, Farquharson G, Filion-Brulotte C, Gingerich J, Godbout L, Grant R, Hamilton W, Kassouf W, Kurban G, Lane K, Lattouf J, Lau D, Leveridge M, McCarthy J, Moore R, North S, O'brien P, Pituskin E, Racine P, Rendon R, So A, Sridhar S, Stubbs K, Su Z, Taylor L, Udall T, Venner P, Vogel W, Yap S, Yau P, Cooper M, Giroux N, Miron D, Mosher D, Ross K, Willacy J. Management of kidney cancer: canadian kidney cancer forum consensus update 2011. Can Urol Assoc J 2012;6:16-22. [PMID: 22396361 DOI: 10.5489/cuaj.11273] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
247 Mickisch GH, Schwander B, Escudier B, Bellmunt J, Maroto JP, Porta C, Walzer S, Siebert U. Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. Clinicoecon Outcomes Res 2011;3:19-27. [PMID: 21935329 DOI: 10.2147/CEOR.S16118] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
248 Miller SM, Wilson LE, Greiner MA, Pritchard JE, Zhang T, Kaye DR, Cohen HJ, Becher RD, Maerz LL, Dinan MA. Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma. J Geriatr Oncol 2022:S1879-4068(21)00651-2. [PMID: 34996724 DOI: 10.1016/j.jgo.2021.12.012] [Reference Citation Analysis]
249 Buti S, Bersanelli M, Donini M, Ardizzoni A. Systemic adjuvant therapies in renal cell carcinoma. Oncol Rev 2012;6:e18. [PMID: 25992216 DOI: 10.4081/oncol.2012.e18] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
250 Mahmoud F, Abdallah AO, Arnaoutakis K, Makhoul I. Metastatic Renal Cell Carcinoma Presenting as Painful Chewing Successfully Treated with Combined Nivolumab and Sunitinib. Perm J 2016;20:15-149. [PMID: 27352410 DOI: 10.7812/TPP/15-149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
251 Bamias A, Karavasilis V, Gavalas N, Tzannis K, Samantas E, Aravantinos G, Koutras A, Gkerzelis I, Kostouros E, Koutsoukos K, Zagouri F, Fountzilas G, Dimopoulos MA. The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study. Int J Clin Oncol 2019;24:411-9. [PMID: 30374686 DOI: 10.1007/s10147-018-1361-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
252 Tannir NM, Figlin RA, Gore ME, Michaelson MD, Motzer RJ, Porta C, Rini BI, Hoang C, Lin X, Escudier B. Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. Clin Genitourin Cancer 2017:S1558-7673(17)30171-4. [PMID: 28711490 DOI: 10.1016/j.clgc.2017.06.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
253 Ansari J, Hussain SA, Ansari A, Glaholm J. Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma. Biologics 2013;7:39-46. [PMID: 23467578 DOI: 10.2147/BTT.S25862] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
254 Li C, Wang R, Ma W, Liu S, Yao X. Do Metastatic Kidney Cancer Patients Benefit From Cytoreductive Nephrectomy? A Real-World Retrospective Study From the SEER Database. Front Surg 2021;8:716455. [PMID: 34557516 DOI: 10.3389/fsurg.2021.716455] [Reference Citation Analysis]
255 Hawkins R, Fife K, Hurst M, Wang M, Naicker N, Nolasco S, Eisen T, Matakidou A, Gordon J. Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK. BMC Cancer 2020;20:670. [PMID: 32680483 DOI: 10.1186/s12885-020-07154-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
256 Zhao T, Wang X, Xu T, Xu X, Liu Z. Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. Oncotarget. 2017;8:51492-51506. [PMID: 28881662 DOI: 10.18632/oncotarget.18190] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
257 Jaiswal V, Jain E, Hitawala G, Loh H, Patel S, Thada P, Nandwana V, Pandey S, Quinonez J, Naz S, Stein JD, Cueva W. Bevacizumab and Sinus Venous Thrombosis: A Literature Review. Cureus 2021;13:e19471. [PMID: 34912612 DOI: 10.7759/cureus.19471] [Reference Citation Analysis]
258 Guo J, Ma J, Sun Y, Qin S, Ye D, Zhou F, He Z, Sheng X, Bi F, Cao D, Chen Y, Huang Y, Liang H, Liang J, Liu J, Liu W, Pan Y, Shu Y, Song X, Wang W, Wang X, Wu X, Xie X, Yao X, Yu S, Zhang Y, Zhou A; written; CSCO Renal Cell Carcinoma Committee. Chinese guidelines on the management of renal cell carcinoma (2015 edition). Ann Transl Med. 2015;3:279. [PMID: 26697439 DOI: 10.3978/j.issn.2305-5839.2015.11.21] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
259 Neuzillet Y, Guy L, Long JA, Zini L, Chevreau C, Duclos B, Escudier B, Gimel P, Joly F, Lang H, Mejean A, Oudard S, Roumeguere T. [Case report of kidney cancer from JOUM 2010]. Prog Urol 2011;21 Suppl 2:S27-33. [PMID: 21397824 DOI: 10.1016/S1166-7087(11)70006-9] [Reference Citation Analysis]
260 Gunnarsson O, Pfanzelter NR, Cohen RB, Keefe SM. Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma. Cancer Manag Res 2015;7:65-73. [PMID: 25709499 DOI: 10.2147/CMAR.S74202] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.9] [Reference Citation Analysis]
261 Pierrard J, Tison T, Grisay G, Seront E. Global management of brain metastasis from renal cell carcinoma. Critical Reviews in Oncology/Hematology 2022. [DOI: 10.1016/j.critrevonc.2022.103600] [Reference Citation Analysis]
262 Maines F, Pilotto S, Milella M, Massari F, Vaccaro V, Felici A, Bria E, Tortora G. “Targeting” renal cell carcinoma patients with “targeted” agents: Are we there yet? World J Clin Urol 2014; 3(1): 9-19 [DOI: 10.5410/wjcu.v3.i1.9] [Reference Citation Analysis]
263 Cohen RB, Oudard S. Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest New Drugs. 2012;30:2066-2079. [PMID: 22327313 DOI: 10.1007/s10637-012-9796-8] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 6.5] [Reference Citation Analysis]
264 Escalante CP, Zalpour A. Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers. Cardiol Res Pract. 2011;2011:816897. [PMID: 21629798 DOI: 10.4061/2011/816897] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
265 Bender RJ, Mac Gabhann F. Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis. BMC Syst Biol 2015;9:55. [PMID: 26341082 DOI: 10.1186/s12918-015-0201-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
266 Cowey CL. Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma. Drug Des Devel Ther. 2013;7:519-527. [PMID: 23818763 DOI: 10.2147/dddt.s31442] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
267 Rini BI, McDermott DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin RA, Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer. 2016;4:81. [PMID: 27891227 DOI: 10.1186/s40425-016-0180-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
268 Yu H, Liu R, Ma B, Li X, Yen HY, Zhou Y, Krasnoperov V, Xia Z, Zhang X, Bove AM, Buscarini M, Parekh D, Gill IS, Liao Q, Tretiakova M, Quinn D, Zhao J, Gill PS. Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma. Br J Cancer 2015;113:616-25. [PMID: 26180925 DOI: 10.1038/bjc.2015.237] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
269 Saijo N. Present status and problems on molecular targeted therapy of cancer. Cancer Res Treat 2012;44:1-10. [PMID: 22500155 DOI: 10.4143/crt.2012.44.1.1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
270 Wanner N, Eden T, Liaukouskaya N, Koch-Nolte F. Nanobodies: new avenue to treat kidney disease. Cell Tissue Res 2021. [PMID: 34131806 DOI: 10.1007/s00441-021-03479-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
271 García del Muro X, Durán I, Perez-gracia JL, Ángel Climent M, Mellado B, Virizuela JA, Castellano DE, González del Alba A, Carbonero I, Álvarez-fernández C, García-donas J, Gil-martin M, Hernández AG. Molecular biomarkers of prognosis in advanced renal cell carcinoma patients treated with Pazopanib plus interferon alpha (INF-2A) in a phase I/IIstudy by the Spanish Oncology Genitourinary Group. Clinical Genitourinary Cancer 2022. [DOI: 10.1016/j.clgc.2022.03.008] [Reference Citation Analysis]
272 Roma A, Maruzzo M, Basso U, Brunello A, Zamarchi R, Bezzon E, Pomerri F, Zovato S, Opocher G, Zagonel V. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response. Fam Cancer 2015;14:309-16. [PMID: 25391617 DOI: 10.1007/s10689-014-9771-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
273 Schmidinger M, Zielinski CC. Defining risk status in the first-line treatment of metastatic renal cell carcinoma. J Cancer Res Clin Oncol 2010;136:961-8. [PMID: 20454802 DOI: 10.1007/s00432-010-0901-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
274 Santos N, Wenger JB, Havre P, Liu Y, Dagan R, Imanirad I, Ivey AM, Zlotecki RA, Algood CB, Gilbert SM, Allegra CJ, Okunieff P, Vieweg J, Dang NH, Luesch H, Dang LH. Combination therapy for renal cell cancer: what are possible options? Oncology 2011;81:220-9. [PMID: 22085914 DOI: 10.1159/000333470] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
275 Meskawi M, Valdivieso R, Dell'Oglio P, Trudeau V, Larcher A, Karakiewicz PI. The Role of Everolimus in Renal Cell Carcinoma. J Kidney Cancer VHL 2015;2:187-94. [PMID: 28326273 DOI: 10.15586/jkcvhl.2015.43] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
276 Courtney KD, Choueiri TK. Updates on novel therapies for metastatic renal cell carcinoma. Ther Adv Med Oncol 2010;2:209-19. [PMID: 21789135 DOI: 10.1177/1758834010361470] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
277 Maroto JP, del Muro XG, Mellado B, Perez-Gracia JL, Andrés R, Cruz J, Gallardo E, Domenech M, Arranz JA, Meana JA. Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC). Clin Transl Oncol 2013;15:698-704. [PMID: 23359179 DOI: 10.1007/s12094-012-0991-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
278 Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs 2014;74:1891-925. [PMID: 25315029 DOI: 10.1007/s40265-014-0302-9] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 15.1] [Reference Citation Analysis]
279 Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist 2010;15:819-25. [PMID: 20688807 DOI: 10.1634/theoncologist.2009-0317] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 6.3] [Reference Citation Analysis]
280 Rini BI, Quinn DI, Baum M, Wood LS, Tarazi J, Rosbrook B, Arruda LS, Cisar L, Roberts WG, Kim S, Motzer RJ. Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Target Oncol 2015;10:45-53. [PMID: 24595903 DOI: 10.1007/s11523-014-0307-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
281 George S, Pili R, Carducci MA, Kim JJ. Role of immunotherapy for renal cell cancer in 2011. J Natl Compr Canc Netw 2011;9:1011-8. [PMID: 21917625 DOI: 10.6004/jnccn.2011.0085] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
282 Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, Fischer P, Ronnen E, Ishill N, Patil S, Motzer RJ. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:1432-1439. [PMID: 19224847 DOI: 10.1200/jco.2008.19.0108] [Cited by in Crossref: 232] [Cited by in F6Publishing: 98] [Article Influence: 17.8] [Reference Citation Analysis]
283 Cressey D. Health economics: Life in the balance. Nature 2009;461:336-9. [PMID: 19759594 DOI: 10.1038/461336a] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
284 Pozzessere C, Bassanelli M, Ceribelli A, Rasul S, Li S, Prior JO, Cicone F. Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer? Curr Urol Rep 2019;20:68. [PMID: 31605269 DOI: 10.1007/s11934-019-0938-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
285 Voss MH, Molina AM, Chen YB, Woo KM, Chaim JL, Coskey DT, Redzematovic A, Wang P, Lee W, Selcuklu SD, Lee CH, Berger MF, Tickoo SK, Reuter VE, Patil S, Hsieh JJ, Motzer RJ, Feldman DR. Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. J Clin Oncol 2016;34:3846-53. [PMID: 27601542 DOI: 10.1200/JCO.2016.67.9084] [Cited by in Crossref: 47] [Cited by in F6Publishing: 20] [Article Influence: 9.4] [Reference Citation Analysis]
286 Smaletz O. Current management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in review. Int Braz J Urol 2015;41:835-43. [PMID: 26689508 DOI: 10.1590/S1677-5538.IBJU.2014.0651] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
287 Sun M, Abdollah F, Schmitges J, Jeldres C, Shariat SF, Perrotte P, Karakiewicz PI. Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma. Open Access J Urol 2011;3:43-8. [PMID: 24198635 DOI: 10.2147/OAJU.S13283] [Reference Citation Analysis]
288 Sullivan LA, Brekken RA. The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2010;2:165-75. [PMID: 20190566 DOI: 10.4161/mabs.2.2.11360] [Cited by in Crossref: 110] [Cited by in F6Publishing: 95] [Article Influence: 10.0] [Reference Citation Analysis]
289 Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L, Porta C, Miceli R, Zilembo N, Bajetta E. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer 2011;104:1256-61. [PMID: 21448165 DOI: 10.1038/bjc.2011.103] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 4.6] [Reference Citation Analysis]
290 Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium--the just price. J Clin Oncol 2013;31:3600-4. [PMID: 23650428 DOI: 10.1200/JCO.2013.49.1845] [Cited by in Crossref: 215] [Cited by in F6Publishing: 77] [Article Influence: 23.9] [Reference Citation Analysis]
291 Ocana A, Ethier JL, Díez-González L, Corrales-Sánchez V, Srikanthan A, Gascón-Escribano MJ, Templeton AJ, Vera-Badillo F, Seruga B, Niraula S, Pandiella A, Amir E. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget 2015;6:39538-49. [PMID: 26446908 DOI: 10.18632/oncotarget.5946] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
292 Escudier B. Comments on the article "Targeted therapy in renal cell carcinoma" by J.-J. Patard et al. World J Urol 2008;26:409-10. [PMID: 18548253 DOI: 10.1007/s00345-008-0280-1] [Reference Citation Analysis]
293 Escudier B, Joly F, Soria JC. [Toxicities of targeted therapies and their management in renal cancer: methodology of guidelines]. Bull Cancer 2011;98:S3-6. [PMID: 25819124 DOI: 10.1684/bdc.2011.1444] [Reference Citation Analysis]
294 Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018;378:1277-90. [PMID: 29562145 DOI: 10.1056/NEJMoa1712126] [Cited by in Crossref: 1646] [Cited by in F6Publishing: 845] [Article Influence: 411.5] [Reference Citation Analysis]
295 Rossi JF, Négrier S, James ND, Kocak I, Hawkins R, Davis H, Prabhakar U, Qin X, Mulders P, Berns B. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 2010;103:1154-62. [PMID: 20808314 DOI: 10.1038/sj.bjc.6605872] [Cited by in Crossref: 130] [Cited by in F6Publishing: 119] [Article Influence: 10.8] [Reference Citation Analysis]
296 Girardi F, Franceschi E, Brandes AA. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Oncologist 2010;15:683-94. [PMID: 20547589 DOI: 10.1634/theoncologist.2009-0235] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
297 Procopio G, Verzoni E, Testa I, Nicolai N, Salvioni R, Debraud F. Experience with sorafenib in the treatment of advanced renal cell carcinoma. Ther Adv Urol 2012;4:303-13. [PMID: 23205057 DOI: 10.1177/1756287212457216] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
298 Négrier S, Raymond E. Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs 2012;30:1791-801. [PMID: 21573959 DOI: 10.1007/s10637-011-9677-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
299 Power DG, Kemeny NE. Nasal septum perforation and bevacizumab. Med Oncol 2011;28:89-93. [PMID: 20213219 DOI: 10.1007/s12032-010-9464-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
300 Hudes GR, Carducci MA, Choueiri TK, Esper P, Jonasch E, Kumar R, Margolin KA, Michaelson MD, Motzer RJ, Pili R, Roethke S, Srinivas S. NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Canc Netw 2011;9 Suppl 1:S1-29. [PMID: 21335444 DOI: 10.6004/jnccn.2011.0124] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
301 Demiselle J, Lheureux S, Clarisse B, Sevin E, Joly F. Metastatic renal cancer: evolution of five complete response cases after the antiangiogenic discontinuation. Bull Cancer 2011. [PMID: 21659064 DOI: 10.1684/bdc.2011.1368] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
302 Hahn AW, Shah AY, Campbell MT. First-Line Immuno-Oncology Combinations for Metastatic Clear Cell Renal Cell Carcinoma (mRCC): A Systematic Review of Phase III Clinical Trials. KCA 2021;5:207-17. [DOI: 10.3233/kca-210123] [Reference Citation Analysis]
303 Nerich V, Hugues M, Paillard MJ, Borowski L, Nai T, Stein U, Nguyen Tan Hon T, Montcuquet P, Maurina T, Mouillet G, Kleinclauss F, Pivot X, Limat S, Thiery-Vuillemin A. Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma. Onco Targets Ther 2014;7:365-74. [PMID: 24600236 DOI: 10.2147/OTT.S56370] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 3.1] [Reference Citation Analysis]
304 Lazăr DC, Tăban S, Cornianu M, Faur A, Goldiş A. New advances in targeted gastric cancer treatment. World J Gastroenterol 2016; 22(30): 6776-6799 [PMID: 27570417 DOI: 10.3748/wjg.v22.i30.6776] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
305 Graser A, Becker CR, Reiser MF, Stief C, Staehler M. [Volumetry of metastases from renal cell carcinoma: comparison with the RECIST criteria]. Radiologe 2008;48:850-6. [PMID: 18806986 DOI: 10.1007/s00117-008-1743-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
306 Arsanious A, Bjarnason GA, Yousef GM. From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma. Mol Cancer 2009;8:20. [PMID: 19291329 DOI: 10.1186/1476-4598-8-20] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
307 Kiesewetter B, Raderer M, Steger GG, Bartsch R, Pirker R, Zöchbauer-Müller S, Prager G, Krainer M, Preusser M, Schmidinger M, Zielinski CC. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. ESMO Open 2016;1:e000066. [PMID: 27843624 DOI: 10.1136/esmoopen-2016-000066] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
308 Yang L, Chen CJ, Guo XL, Wu XC, Lv BJ, Wang HL, Guo Z, Zhao XY. Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis. J Neurooncol 2018;137:49-56. [PMID: 29170906 DOI: 10.1007/s11060-017-2693-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
309 Schmidt E, Lister J, Neumann M, Wiecek W, Fu S, Vataire AL, Sostar J, Huang S, Marteau F. Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis. Target Oncol 2018;13:205-16. [PMID: 29492762 DOI: 10.1007/s11523-018-0559-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
310 Gan HK, Seruga B, Knox JJ. Targeted therapies for renal cell carcinoma: more gains from using them again. Curr Oncol 2009;16 Suppl 1:S45-51. [PMID: 19478898 DOI: 10.3747/co.v16i0.404] [Reference Citation Analysis]
311 Liu F, Chen X, Peng E, Guan W, Li Y, Hu Z, Ye Z, Zhuang Q. VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials. J Huazhong Univ Sci Technolog Med Sci 2011;31:799-806. [PMID: 22173502 DOI: 10.1007/s11596-011-0680-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
312 Croom KF, Dhillon S. Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer. Drugs 2011;71:2213-29. [PMID: 22035518 DOI: 10.2165/11207720-000000000-00000] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
313 Guo J, Huang Y, Zhang X, Zhou F, Sun Y, Qin S, Ye Z, Wang H, Jappe A, Straub P, Pirotta N, Gogov S. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study. BMC Cancer 2013;13:136. [PMID: 23514360 DOI: 10.1186/1471-2407-13-136] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
314 Wang J, Li X, Wu X, Wang Z, Zhang C, Cao G, Zhang X, Peng F, Yan T. Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis. EBioMedicine 2019;47:78-88. [PMID: 31439476 DOI: 10.1016/j.ebiom.2019.08.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
315 Grünberger B. [Systemic treatment of renal cell carcinoma - recent update]. Wien Med Wochenschr 2011;161:382-6. [PMID: 21953429 DOI: 10.1007/s10354-011-0016-5] [Reference Citation Analysis]
316 Yalçın Ş, Yildiz R, Dane F, Karaoğlu A, Öksüzoğlu B, Özyılkan Ö, Sevinç A, Özdemir F, Turna H, Uslu R, Ulay E. A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey - NOTES study. Onco Targets Ther 2018;11:1223-8. [PMID: 29551901 DOI: 10.2147/OTT.S148917] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
317 Ravoori MK, Nishimura M, Singh SP, Lu C, Han L, Hobbs BP, Pradeep S, Choi HJ, Bankson JA, Sood AK, Kundra V. Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model. PLoS One 2015;10:e0131095. [PMID: 26098849 DOI: 10.1371/journal.pone.0131095] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
318 Strickler JH, Starodub AN, Jia J, Meadows KL, Nixon AB, Dellinger A, Morse MA, Uronis HE, Marcom PK, Zafar SY, Haley ST, Hurwitz HI. Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. Cancer Chemother Pharmacol. 2012;70:251-258. [PMID: 22744359 DOI: 10.1007/s00280-012-1911-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
319 Gerullis H, Bergmann L, Maute L, Ecke TH, Eimer C, Bagner JW, Otto T. Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Med Oncol 2010;27:373-8. [PMID: 19399651 DOI: 10.1007/s12032-009-9220-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
320 Baxevanis CN. Antibody-based cancer therapy. Expert Opin Drug Discov 2008;3:441-52. [PMID: 23489099 DOI: 10.1517/17460441.3.4.441] [Reference Citation Analysis]
321 Grimm MO, Wolff I, Zastrow S, Fröhner M, Wirth M. Advances in renal cell carcinoma treatment. Ther Adv Urol 2010;2:11-7. [PMID: 21789079 DOI: 10.1177/1756287210364959] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
322 Calvo E, Porta C, Grünwald V, Escudier B. The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma. Oncologist 2019;24:338-48. [PMID: 30158285 DOI: 10.1634/theoncologist.2018-0267] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
323 Shih YC, Chien CR, Xu Y, Pan IW, Smith GL, Buchholz TA. Economic burden of renal cell carcinoma: Part I--an updated review. Pharmacoeconomics 2011;29:315-29. [PMID: 21395351 DOI: 10.2165/11586100-000000000-00000] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
324 Antonaci G, Cossa LG, Muscella A, Vetrugno C, De Pascali SA, Fanizzi FP, Marsigliante S. [Pt(O,O'-acac)(γ-acac)(DMS)] Induces Autophagy in Caki-1 Renal Cancer Cells. Biomolecules 2019;9:E92. [PMID: 30845773 DOI: 10.3390/biom9030092] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
325 Kelly-Morland C, Rudman S, Nathan P, Mallett S, Montana G, Cook G, Goh V. Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study. BMC Cancer 2017;17:392. [PMID: 28578690 DOI: 10.1186/s12885-017-3371-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
326 Han K, Peyret T, Marchand M, Quartino A, Gosselin NH, Girish S, Allison DE, Jin J. Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemother Pharmacol 2016;78:341-51. [PMID: 27329360 DOI: 10.1007/s00280-016-3079-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
327 Marín-Pozo JF, Duarte-Pérez JM, Sánchez-Rovira P. Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience. Medicine (Baltimore) 2016;95:e3623. [PMID: 27175672 DOI: 10.1097/MD.0000000000003623] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
328 Dong M, Liao JK, Yan B, Li R, Zhang M, Yu CM. A combination of increased Rho kinase activity and N-terminal pro-B-type natriuretic peptide predicts worse cardiovascular outcome in patients with acute coronary syndrome. Int J Cardiol. 2013;167:2813-2819. [PMID: 22921817 DOI: 10.1016/j.ijcard.2012.07.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
329 Wang H, Man L, Li G, Huang G, Wang J. Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis. Onco Targets Ther 2016;9:3423-32. [PMID: 27354814 DOI: 10.2147/OTT.S100706] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
330 Zhang J, Zhang Y, Tang S, Jiang L, He Q, Hamblin LT, He J, Xu Z, Wu J, Chen Y, Liang H, Chen D, Huang Y, Wang X, Deng K, Jiang S, Zhou J, Xu J, Chen X, Liang W, He J. Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour. BMJ Open 2018;8:e017240. [PMID: 30206071 DOI: 10.1136/bmjopen-2017-017240] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
331 Jia YY, Yu Y, Li HJ. POSTN promotes proliferation and epithelial-mesenchymal transition in renal cell carcinoma through ILK/AKT/mTOR pathway. J Cancer 2021;12:4183-95. [PMID: 34093819 DOI: 10.7150/jca.51253] [Reference Citation Analysis]
332 Bedke J, Gauler T, Grünwald V, Hegele A, Herrmann E, Hinz S, Janssen J, Schmitz S, Schostak M, Tesch H, Zastrow S, Miller K. Systemic therapy in metastatic renal cell carcinoma. World J Urol 2017;35:179-88. [PMID: 27277600 DOI: 10.1007/s00345-016-1868-5] [Cited by in Crossref: 69] [Cited by in F6Publishing: 73] [Article Influence: 11.5] [Reference Citation Analysis]
333 Sepe P, Mennitto A, Corti F, Procopio G. Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma. Immunotargets Ther 2020;9:273-88. [PMID: 33224904 DOI: 10.2147/ITT.S240889] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
334 Kontovinis L, Laschos K, Karadimou A, Andreadis C, Bamias A, Paraskevopoulos P, Dimopoulos M, Papazisis K. Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. Med Oncol 2012;29:750-4. [PMID: 21279702 DOI: 10.1007/s12032-010-9815-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
335 Tsimafeyeu I, Snegovoy A, Varlamov S, Safina S, Varlamov I, Gurina L, Manzuk L. Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T. Target Oncol 2015;10:423-7. [PMID: 25466382 DOI: 10.1007/s11523-014-0347-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
336 Wild JR, Staton CA, Chapple K, Corfe BM. Neuropilins: expression and roles in the epithelium. Int J Exp Pathol 2012;93:81-103. [PMID: 22414290 DOI: 10.1111/j.1365-2613.2012.00810.x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 8.1] [Reference Citation Analysis]
337 Alsharm A, Bazarbashi S, Alghamdi A, Alkhateeb S, Aljubran A, Abusamra A, Alharbi H, Alotaibi M, Almansour M, Alkushi H, Ahmed I, Murshid E, Eltijani A, Rabah D. Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma 2017. Urol Ann 2018;10:123-32. [PMID: 29719321 DOI: 10.4103/UA.UA_175_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
338 Audenet F, Rouprêt M, Méjean A. [Renal cell carcinoma and antiangiogenic agents: ongoing controversies are seeking answers for improvement of therapeutic management]. Prog Urol 2009;19:596-605. [PMID: 19800548 DOI: 10.1016/j.purol.2009.05.009] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
339 Weinstock M, McDermott D. Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol 2015;7:365-77. [PMID: 26622321 DOI: 10.1177/1756287215597647] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 11.0] [Reference Citation Analysis]
340 Escudier B, Cosaert J, Jethwa S. Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. Biologics 2008;2:517-30. [PMID: 19707382 DOI: 10.2147/btt.s3509] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
341 Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12:237-251. [PMID: 22437869 DOI: 10.1038/nrc3237] [Cited by in Crossref: 847] [Cited by in F6Publishing: 798] [Article Influence: 84.7] [Reference Citation Analysis]
342 Liu KG, Gupta S, Goel S. Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects. Oncotarget 2017;8:17313-27. [PMID: 28061473 DOI: 10.18632/oncotarget.14388] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
343 Zarrabi K, Fang C, Wu S. New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy. J Hematol Oncol 2017;10:38. [PMID: 28153029 DOI: 10.1186/s13045-016-0374-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 7.8] [Reference Citation Analysis]
344 Romero-Laorden N, Doger B, Hernandez M, Hernandez C, Rodriguez-Moreno JF, Garcia-Donas J. Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma. Clin Transl Oncol 2016;18:1-8. [PMID: 26169213 DOI: 10.1007/s12094-015-1332-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
345 Villa G, Hernández-Pastor LJ. Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain. BMC Cancer 2013;13:399. [PMID: 24004638 DOI: 10.1186/1471-2407-13-399] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
346 Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Motzer RJ. Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α. Br J Cancer 2012;106:1587-90. [PMID: 22568998 DOI: 10.1038/bjc.2012.149] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
347 Aziz SA, Sznol J, Adeniran A, Colberg JW, Camp RL, Kluger HM. Vascularity of primary and metastatic renal cell carcinoma specimens. J Transl Med 2013;11:15. [PMID: 23316728 DOI: 10.1186/1479-5876-11-15] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
348 Gupta S, Spiess PE. The prospects of pazopanib in advanced renal cell carcinoma. Ther Adv Urol 2013;5:223-32. [PMID: 24082917 DOI: 10.1177/1756287213495099] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
349 Dominietto M, Dobosz M, Bürgi S, Renner A, Zahlmann G, Scheuer W, Rudin M. Quantification of antiangiogenic treatment effects on tissue heterogeneity in glioma tumour xenograft model using a combination of DCE-MRI and 3D-ultramicroscopy. Eur Radiol 2017;27:2894-902. [PMID: 27830379 DOI: 10.1007/s00330-016-4629-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
350 Poprach A, Bortlíček Z, Büchler T, Melichar B, Lakomý R, Vyzula R, Brabec P, Svoboda M, Dušek L, Gregor J. Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database. Med Oncol 2012;29:3314-20. [PMID: 22752571 DOI: 10.1007/s12032-012-0286-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
351 Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs R D. 2011;11:113-126. [PMID: 21679004 DOI: 10.2165/11591240-000000000-00000] [Cited by in Crossref: 86] [Cited by in F6Publishing: 90] [Article Influence: 8.6] [Reference Citation Analysis]
352 Bang HJ, Littrup PJ, Goodrich DJ, Currier BP, Aoun HD, Heilbrun LK, Vaishampayan U, Adam B, Goodman AC. Percutaneous cryoablation of metastatic renal cell carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliation. J Vasc Interv Radiol 2012;23:770-7. [PMID: 22538119 DOI: 10.1016/j.jvir.2012.03.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 6.2] [Reference Citation Analysis]
353 Eto M, Uemura H, Tomita Y, Kanayama H, Shinohara N, Kamei Y, Fujii Y, Umeyama Y, Ozono S, Naito S, Akaza H; Japan Axitinib Phase II Study Group. Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma. Cancer Sci 2014;105:1576-83. [PMID: 25283266 DOI: 10.1111/cas.12546] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
354 Levin PA, Dowell JE. Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date. Onco Targets Ther 2017;10:2057-66. [PMID: 28435296 DOI: 10.2147/OTT.S113598] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
355 Napolitano V, Tamagnone L. Neuropilins Controlling Cancer Therapy Responsiveness. Int J Mol Sci 2019;20:E2049. [PMID: 31027288 DOI: 10.3390/ijms20082049] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
356 Hacker KE, Rathmell WK. Emerging molecular classification in renal cell carcinoma: implications for drug development. Target Oncol 2010;5:75-84. [PMID: 20645016 DOI: 10.1007/s11523-010-0144-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
357 Isono T, Suzaki M. Analysis of the characteristics of chemotherapy-resistant renal cell carcinomas based on global transcriptional analysis of their tissues and cell lines. PLoS One 2019;14:e0225721. [PMID: 31774870 DOI: 10.1371/journal.pone.0225721] [Reference Citation Analysis]
358 Bukowski RM. Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma. Cancer Manag Res 2011;3:273-85. [PMID: 21931501 DOI: 10.2147/CMR.S15557] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
359 Pories SE, Wulf GM. Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review. Breast Cancer (Dove Med Press) 2010;2:37-44. [PMID: 24367165 DOI: 10.2147/bctt.s6511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
360 Sakurai K, Muguruma K, Yamazoe S, Kimura K, Toyokawa T, Amano R, Kubo N, Tanaka H, Yashiro M, Ohira M, Hirakawa K. Gastric metastasis from renal cell carcinoma with gastrointestinal bleeding: a case report and review of the literature. Int Surg 2014;99:86-90. [PMID: 24444276 DOI: 10.9738/INTSURG-D-13-00115.1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
361 Beisland C, Johannesen TB, Klepp O, Axcrona U, Torgersen KM, Kowalski J, Solli O, Sandin R, Oldenburg J. Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study. Onco Targets Ther 2017;10:371-85. [PMID: 28144152 DOI: 10.2147/OTT.S123061] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
362 Tang W, McCormick A, Li J, Masson E. Clinical Pharmacokinetics and Pharmacodynamics of Cediranib. Clin Pharmacokinet 2017;56:689-702. [PMID: 27943222 DOI: 10.1007/s40262-016-0488-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
363 Esther J, Hale P, Hahn AW, Agarwal N, Maughan BL. Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors. Drugs Aging 2019;36:395-401. [PMID: 30784023 DOI: 10.1007/s40266-019-00644-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
364 Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, Chen D, Rosen O. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 2013;18:273-80. [PMID: 23485622 DOI: 10.1634/theoncologist.2012-0339] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 8.2] [Reference Citation Analysis]
365 Bracarda S, Porta C, Sisani M, Marrocolo F, Paglino C, Hamzaj A, D Buono S, Sternberg CN. Comparing comparators: a look at control arms in kidney cancer studies over the years. Br J Cancer 2015;112:14-9. [PMID: 25375270 DOI: 10.1038/bjc.2014.240] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
366 Yoon SH, Kim KH, Choi J, Kim GM, Kim JH, Kim HS, Park YN, Rha SY. Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis. Cancer Res Treat 2010;42:180-4. [PMID: 20948925 DOI: 10.4143/crt.2010.42.3.180] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
367 Seidel C, Busch J, Weikert S, Steffens S, Bokemeyer C, Grünwald V. Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC). Br J Cancer 2013;109:2998-3004. [PMID: 24169357 DOI: 10.1038/bjc.2013.662] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
368 Holland BC, Shetty Z, Alanee S. The Effect of Targeted Therapy for Genitourinary Malignancies on Sexual Function and Fertility. Curr Urol Rep 2017;18:65. [PMID: 28712040 DOI: 10.1007/s11934-017-0704-9] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
369 Li X, Li Y, Lu W, Chen M, Ye W, Zhang D. The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis. Cells 2019;8:E1602. [PMID: 31835465 DOI: 10.3390/cells8121602] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
370 Rhee H, Blazak J, Tham CM, Ng KL, Shepherd B, Lawson M, Preston J, Vela I, Thomas P, Wood S. Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. EJNMMI Res 2016;6:76. [PMID: 27771904 DOI: 10.1186/s13550-016-0231-6] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 8.5] [Reference Citation Analysis]
371 Hong B, Yang Y, Guo S, Duoerkun S, Deng X, Chen D, Yu S, Qian W, Li Q, Li Q, Gong K, Zhang N. Intra-tumour molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft models. Oncotarget 2017;8:49839-50. [PMID: 28548943 DOI: 10.18632/oncotarget.17765] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
372 Seebacher NA, Stacy AE, Porter GM, Merlot AM. Clinical development of targeted and immune based anti-cancer therapies. J Exp Clin Cancer Res 2019;38:156. [PMID: 30975211 DOI: 10.1186/s13046-019-1094-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 19.3] [Reference Citation Analysis]
373 Tomita Y, Fukasawa S, Oya M, Uemura H, Shinohara N, Habuchi T, Rini BI, Chen Y, Bair AH, Ozono S, Naito S, Akaza H. Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study. Jpn J Clin Oncol 2016;46:1031-41. [PMID: 27572087 DOI: 10.1093/jjco/hyw103] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
374 Incorvaia L, Bronte G, Bazan V, Badalamenti G, Rizzo S, Pantuso G, Natoli C, Russo A. Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma. Oncotarget 2016;7:21259-71. [PMID: 26872372 DOI: 10.18632/oncotarget.7267] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
375 Steiner T, Mickisch GH. [Metastatic renal cell carcinoma: primary and follow-up treatment]. Urologe A 2013;52:1529-30, 1532-3. [PMID: 24170300 DOI: 10.1007/s00120-013-3248-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
376 Aragon-Ching JB, Dahut WL. Anti-angiogenesis approach to genitourinary cancer treatment. Update Cancer Ther 2009;3:182-8. [PMID: 19774201 DOI: 10.1016/j.uct.2009.05.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
377 Zekri J, Dreosti LM, Ghosn M, Hamada E, Jaloudi M, Khorshid O, Larbaoui B. Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement. J Multidiscip Healthc 2015;8:335-44. [PMID: 26251610 DOI: 10.2147/JMDH.S85538] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
378 Pouessel D, Patard JJ, Culine S. [Advanced renal carcinomas with special situations. How to treat them?]. Bull Cancer 2010;97:83-90. [PMID: 20418207 DOI: 10.1684/bdc.2010.1073] [Reference Citation Analysis]
379 Merza H, Bilusic M. Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. Curr Oncol Rep 2017;19:27. [PMID: 28303494 DOI: 10.1007/s11912-017-0583-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
380 Fisher R, Larkin J. Renal cell cancer: what can we learn from pre-operative studies? Front Oncol 2011;1:51. [PMID: 22655250 DOI: 10.3389/fonc.2011.00051] [Reference Citation Analysis]
381 Larkin JM, Pyle LM, Gore ME. Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies. Oncologist 2010;15:1135-46. [PMID: 21051659 DOI: 10.1634/theoncologist.2010-0078] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
382 Bharthuar A. Metastatic renal cell carcinoma: Current scenario and future trends. South Asian J Cancer 2012;1:30-5. [PMID: 24455506 DOI: 10.4103/2278-330X.96505] [Reference Citation Analysis]
383 Keefe D, Bowen J, Gibson R, Tan T, Okera M, Stringer A. Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist 2011;16:432-44. [PMID: 21441297 DOI: 10.1634/theoncologist.2010-0271] [Cited by in Crossref: 62] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
384 Cowey CL, Sonpavde G, Hutson TE. New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib. Onco Targets Ther. 2010;3:147-155. [PMID: 21049083 DOI: 10.2147/ott.s12480] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
385 Unverzagt S, Moldenhauer I, Nothacker M, Roßmeißl D, Hadjinicolaou AV, Peinemann F, Greco F, Seliger B. Immunotherapy for metastatic renal cell carcinoma. Cochrane Database Syst Rev 2017;5:CD011673. [PMID: 28504837 DOI: 10.1002/14651858.CD011673.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
386 Heng DY, Mackenzie MJ, Vaishampayan UN, Bjarnason GA, Knox JJ, Tan MH, Wood L, Wang Y, Kollmannsberger C, North S. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol. 2012;23:1549-1555. [PMID: 22056973 DOI: 10.1093/annonc/mdr533] [Cited by in Crossref: 90] [Cited by in F6Publishing: 96] [Article Influence: 8.2] [Reference Citation Analysis]
387 Maiti A, Nemati-Shafaee M, Msaouel P, Pagliaro LC, Jonasch E, Tannir NM, Shah AY. Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. Clin Genitourin Cancer 2017:S1558-7673(17)30238-0. [PMID: 28870517 DOI: 10.1016/j.clgc.2017.07.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
388 Izzedine H. Anti-VEGF Cancer Therapy in Nephrology Practice. Int J Nephrol 2014;2014:143426. [PMID: 25210627 DOI: 10.1155/2014/143426] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
389 Corvigno S, Frödin M, Wisman GBA, Nijman HW, Van der Zee AG, Jirström K, Nodin B, Hrynchyk I, Edler D, Ragnhammar P, Johansson M, Dahlstrand H, Mezheyeuski A, Östman A. Multi-parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumour-type-specific stroma phenotypes and a novel vascular biomarker. J Pathol Clin Res 2017;3:214-24. [PMID: 28770105 DOI: 10.1002/cjp2.74] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
390 Abel EJ, Wood CG. Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol. 2009;6:375-383. [PMID: 19528960 DOI: 10.1038/nrurol.2009.102] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
391 Négrier S, Pérol D, Bahleda R, Hollebecque A, Chatelut E, Boyle H, Cassier P, Metzger S, Blanc E, Soria JC, Escudier B. Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors. BMC Cancer 2017;17:547. [PMID: 28810837 DOI: 10.1186/s12885-017-3527-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
392 Wang Y, Zhang J, Wu Y, Ding ZY, Luo XM, Liu J, Zhong WN, Deng GH, Xia XY, Deng YT, Wei YQ, Jiang Y. Mannan-modified adenovirus targeting TERT and VEGFR-2: A universal tumour vaccine. Sci Rep 2015;5:11275. [PMID: 26085010 DOI: 10.1038/srep11275] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
393 Yoo B, Fuchs BC, Medarova Z. New Directions in the Study and Treatment of Metastatic Cancer. Front Oncol 2018;8:258. [PMID: 30042926 DOI: 10.3389/fonc.2018.00258] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
394 Procopio G, Bellmunt J, Dutcher J, Bracarda S, Knox J, Brueckner A, Molnar I, Escudier B, Hutson TE. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. Br J Cancer 2013;108:311-8. [PMID: 23322192 DOI: 10.1038/bjc.2012.543] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
395 Shinohara N, Obara W, Tatsugami K, Naito S, Kamba T, Takahashi M, Murai S, Abe T, Oba K, Naito S. Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy. Cancer Sci 2015;106:618-26. [PMID: 25711777 DOI: 10.1111/cas.12646] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
396 McKay RR, Zurita AJ, Werner L, Bruce JY, Carducci MA, Stein MN, Heath EI, Hussain A, Tran HT, Sweeney CJ, Ross RW, Kantoff PW, Slovin SF, Taplin ME. A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy. J Clin Oncol 2016;34:1913-20. [PMID: 27044933 DOI: 10.1200/JCO.2015.65.3154] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
397 Rangwala F, Bendell JC, Kozloff MF, Arrowood CC, Dellinger A, Meadows J, Tourt-Uhlig S, Murphy J, Meadows KL, Starr A, Broderick S, Brady JC, Cushman SM, Morse MA, Uronis HE, Hsu SD, Zafar SY, Wallace J, Starodub AN, Strickler JH, Pang H, Nixon AB, Hurwitz HI. Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. Invest New Drugs 2014;32:700-9. [PMID: 24711126 DOI: 10.1007/s10637-014-0089-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
398 Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 2011;16 Suppl 2:32-44. [PMID: 21346038 DOI: 10.1634/theoncologist.2011-S2-32] [Cited by in Crossref: 58] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
399 Bellmunt J, Gelabert-Mas A. [New cell target treatments: indications, results and tolerance]. Actas Urol Esp 2009;33:609-14. [PMID: 19658316 DOI: 10.1016/s0210-4806(09)74196-8] [Reference Citation Analysis]
400 Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer 2018;94:115-25. [PMID: 29550566 DOI: 10.1016/j.ejca.2018.02.012] [Cited by in Crossref: 139] [Cited by in F6Publishing: 120] [Article Influence: 34.8] [Reference Citation Analysis]
401 Sahi C, Knox JJ, Clemons M, Joshua AM, Broom R. Renal cell carcinoma bone metastases: clinical advances. Ther Adv Med Oncol 2010;2:75-83. [PMID: 21789128 DOI: 10.1177/1758834009358417] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
402 Sun J, Wang X, Tang B, Liu H, Zhang M, Wang Y, Ping F, Ding J, Shen A, Geng M. A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma. Theranostics 2018;8:3256-67. [PMID: 29930727 DOI: 10.7150/thno.23964] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
403 Naglieri E. Management of toxicity in patients treated with tyrosine kinase inhibitors (TKI). European Journal of Cancer Supplements 2008;6:42-5. [DOI: 10.1016/j.ejcsup.2008.06.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
404 Ades S, Pulluri B, Holmes CE, Lal I, Kumar S, Littenberg B. Risk factors for venous thromboembolism in metastatic colorectal cancer with contemporary treatment: A SEER-Medicare analysis. Cancer Med 2022. [PMID: 35129311 DOI: 10.1002/cam4.4581] [Reference Citation Analysis]
405 Moscetti L, Hennik P, Bolstad B, Camarero J, Josephson F, Melchiorri D, Sommerfelt Grønvold M, Sjoberg J, Botezatu M, Mulder J, Meulendijks D, Trullas Jimeno A, Zafiropoulos N, Bergh J, Enzmann H, Pignatti F. Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects. ESMO Open 2020;5:e000856. [PMID: 32847837 DOI: 10.1136/esmoopen-2020-000856] [Reference Citation Analysis]
406 Franco M, Roswall P, Cortez E, Hanahan D, Pietras K. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood 2011;118:2906-17. [PMID: 21778339 DOI: 10.1182/blood-2011-01-331694] [Cited by in Crossref: 184] [Cited by in F6Publishing: 175] [Article Influence: 16.7] [Reference Citation Analysis]
407 Alesini D, Mosillo C, Naso G, Cortesi E, Iacovelli R. Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma. Ther Adv Urol 2015;7:286-94. [PMID: 26425143 DOI: 10.1177/1756287215591764] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
408 Burotto M, Wilkerson J, Stein W, Motzer R, Bates S, Fojo T. Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example. PLoS One. 2014;9:e96316. [PMID: 24796484 DOI: 10.1371/journal.pone.0096316] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
409 Elamin YY, Rafee S, Toomey S, Hennessy BT. Immune effects of bevacizumab: killing two birds with one stone. Cancer Microenviron. 2015;8:15-21. [PMID: 25326055 DOI: 10.1007/s12307-014-0160-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
410 Santos ES, Gomez JE, Raez LE. Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor. Invest New Drugs 2012;30:1261-9. [PMID: 21350804 DOI: 10.1007/s10637-011-9644-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
411 Altoos B, Amini A, Yacoub M, Bourlon MT, Kessler EE, Flaig TW, Fisher CM, Kavanagh BD, Lam ET, Karam SD. Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT). Radiat Oncol 2015;10:218. [PMID: 26510665 DOI: 10.1186/s13014-015-0528-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
412 Danciu OC, Rayani S, Michals EA, Villano JL. Prolonged activity of bevacizumab in adenocarcinoma of the lung with multiple brain metastases. Med Oncol 2012;29:2619-22. [PMID: 22209841 DOI: 10.1007/s12032-011-0148-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
413 Tang PA, Hay AE, O'Callaghan CJ, Mittmann N, Chambers CR, Pater JL, Leighl NB. Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada. Curr Oncol 2016;23:S7-S13. [PMID: 26985151 DOI: 10.3747/co.23.2861] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
414 Gill DM, Hahn AW, Hale P, Maughan BL. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma. Curr Treat Options Oncol 2018;19:6. [PMID: 29368125 DOI: 10.1007/s11864-018-0517-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
415 Roodink I, Verrijp K, Raats J, Leenders WP. Plexin D1 is ubiquitously expressed on tumor vessels and tumor cells in solid malignancies. BMC Cancer 2009;9:297. [PMID: 19703316 DOI: 10.1186/1471-2407-9-297] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
416 Scaringi C, Enrici RM, Minniti G. Combining molecular targeted agents with radiation therapy for malignant gliomas. Onco Targets Ther 2013;6:1079-95. [PMID: 23966794 DOI: 10.2147/OTT.S48224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.2] [Reference Citation Analysis]
417 Yuasa T, Urasaki T, Oki R. Recent Advances in Medical Therapy for Urological Cancers. Front Oncol 2022;12:746922. [DOI: 10.3389/fonc.2022.746922] [Reference Citation Analysis]
418 Bamias A, Tzannis K, Beuselinck B, Oudard S, Escudier B, Diosynopoulos D, Papazisis K, Lang H, Wolter P, de Guillebon E, Stravodimos K, Chrisofos M, Fountzilas G, Elaidi RT, Dimopoulos MA, Bamia C. Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration. Br J Cancer 2013;109:332-41. [PMID: 23807171 DOI: 10.1038/bjc.2013.341] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
419 Schwartz JL, Shajahan AN, Clarke R. The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer. Int J Breast Cancer 2011;2011:912102. [PMID: 22295238 DOI: 10.4061/2011/912102] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
420 Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol. 2014;73:495-501. [PMID: 24435060 DOI: 10.1007/s00280-014-2384-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
421 Leighl NB, Bennouna J, Yi J, Moore N, Hambleton J, Hurwitz H. Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. Br J Cancer. 2011;104:413-418. [PMID: 21245868 DOI: 10.1038/sj.bjc.6606074] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
422 Hoshino Y, Hasegawa H, Ishii Y, Endo T, Ochiai H, Okabayashi K, Kaneko G, Mikami S, Mukai M, Oya M, Kitagawa Y. Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma. Int J Clin Oncol 2012;17:412-6. [PMID: 21927829 DOI: 10.1007/s10147-011-0318-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
423 Laskey RA, Richard SD, Smith AL, Lin JF, Beck TL, Lesnock JL, Kelley JL 3rd, Olawaiye AB, Sukumvanich P, Krivak TC. Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity. Onco Targets Ther 2014;7:469-76. [PMID: 24711703 DOI: 10.2147/OTT.S57425] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
424 Wang HT, Xia M. A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma. Medicine (Baltimore) 2019;98:e13779. [PMID: 30608388 DOI: 10.1097/MD.0000000000013779] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
425 Bullock KE, Petros WP, Younis I, Uronis HE, Morse MA, Blobe GC, Zafar SY, Gockerman JP, Lager JJ, Truax R, Meadows KL, Howard LA, O'Neill MM, Broadwater G, Hurwitz HI, Bendell JC. A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemother Pharmacol 2011;67:465-74. [PMID: 21079958 DOI: 10.1007/s00280-010-1507-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
426 Gao X, McDermott DF. Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma. Expert Opin Biol Ther 2018;18:947-57. [PMID: 30124333 DOI: 10.1080/14712598.2018.1513485] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
427 Molina AM, Motzer RJ. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist 2011;16 Suppl 2:45-50. [PMID: 21346039 DOI: 10.1634/theoncologist.2011-S2-45] [Cited by in Crossref: 56] [Cited by in F6Publishing: 25] [Article Influence: 5.1] [Reference Citation Analysis]
428 Anker J, Miller J, Taylor N, Kyprianou N, Tsao CK. From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma. Cells 2021;10:3231. [PMID: 34831452 DOI: 10.3390/cells10113231] [Reference Citation Analysis]
429 Kraemer A, Hauser S, Kim Y, Gorschlüter M, Müller SC, Brossart P, Schmidt-Wolf IG. Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide. Ger Med Sci 2009;7:Doc04. [PMID: 19675744 DOI: 10.3205/000063] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
430 Stein WD, Wilkerson J, Kim ST, Huang X, Motzer RJ, Fojo AT, Bates SE. Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth. Clin Cancer Res 2012;18:2374-81. [PMID: 22344231 DOI: 10.1158/1078-0432.CCR-11-2275] [Cited by in Crossref: 47] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
431 Carlo MI, Voss MH, Motzer RJ. Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nat Rev Urol 2016;13:420-31. [PMID: 27324121 DOI: 10.1038/nrurol.2016.103] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 8.8] [Reference Citation Analysis]
432 Chu D, Wu S. Novel therapies in genitourinary cancer: an update. J Hematol Oncol 2008;1:11. [PMID: 18694493 DOI: 10.1186/1756-8722-1-11] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
433 Perez-Gracia JL, Prior C, Guillén-Grima F, Segura V, Gonzalez A, Panizo A, Melero I, Grande-Pulido E, Gurpide A, Gil-Bazo I, Calvo A. Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer 2009;101:1876-83. [PMID: 19904265 DOI: 10.1038/sj.bjc.6605409] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 4.7] [Reference Citation Analysis]
434 Gupta S, Parsa V, Heilbrun LK, Smith DW, Dickow B, Heath E, Vaishampayan U. Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction. Anticancer Drugs 2011;22:794-800. [PMID: 21799472 DOI: 10.1097/CAD.0b013e328346af0d] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
435 Bellmunt J, Puente J, Garcia de Muro J, Lainez N, Rodríguez C, Duran I. SEOM clinical guidelines for the treatment of renal cell carcinoma. Clin Transl Oncol. 2014;16:1043-1050. [PMID: 25274276 DOI: 10.1007/s12094-014-1219-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
436 Marona P, Górka J, Kotlinowski J, Majka M, Jura J, Miekus K. C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas. Cells 2019;8:E272. [PMID: 30909397 DOI: 10.3390/cells8030272] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
437 Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer 2010;102:80-6. [PMID: 19920817 DOI: 10.1038/sj.bjc.6605417] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
438 Blumenthal DT, Mendel L, Bokstein F. The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter? J Neurooncol 2016;127:493-502. [PMID: 26721244 DOI: 10.1007/s11060-015-2025-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
439 Ho JY, Hsu RJ, Wu CL, Chang WL, Cha TL, Yu DS, Yu CP. Ovatodiolide Targets β -Catenin Signaling in Suppressing Tumorigenesis and Overcoming Drug Resistance in Renal Cell Carcinoma. Evid Based Complement Alternat Med 2013;2013:161628. [PMID: 23781255 DOI: 10.1155/2013/161628] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
440 Crane CH, Winter K, Regine WF, Safran H, Rich TA, Curran W, Wolff RA, Willett CG. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol. 2009;27:4096-4102. [PMID: 19636002 DOI: 10.1200/jco.2009.21.852] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
441 Pan D, Schmieder AH, Wang K, Yang X, Senpan A, Cui G, Killgore K, Kim B, Allen JS, Zhang H, Caruthers SD, Shen B, Wickline SA, Lanza GM. Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β₃-targeted theranostic nanoparticles. Theranostics 2014;4:565-78. [PMID: 24723979 DOI: 10.7150/thno.7581] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
442 Mills EJ, Rachlis B, O'Regan C, Thabane L, Perri D. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer 2009;9:34. [PMID: 19173737 DOI: 10.1186/1471-2407-9-34] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
443 Drai J, Pignot G, Bessede T, Boulière F, Hammoudi Y, Ferlicot S, Patard JJ. [New anti-angiogenic strategies in the management of kidney cancer]. Prog Urol 2013;23:841-8. [PMID: 24034795 DOI: 10.1016/j.purol.2013.01.024] [Reference Citation Analysis]
444 Sun M, Shariat SF, Trinh QD, Meskawi M, Bianchi M, Hansen J, Abdollah F, Perrotte P, Karakiewicz PI. An evidence-based guide to the selection of sequential therapies in metastatic renal cell carcinoma. Ther Adv Urol 2013;5:121-8. [PMID: 23554847 DOI: 10.1177/1756287212466128] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
445 Pili R, Jegede O, Carducci MA, Manola J, Groteluschen DL, Appleman LL, Liu G, Shanks JC, Dakhil SR, Dutcher J, DiPaola RS. A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805]). Clin Genitourin Cancer 2017;15:642-651.e1. [PMID: 28545998 DOI: 10.1016/j.clgc.2017.04.023] [Reference Citation Analysis]
446 Burotto M, Edgerly M, Velarde M, Balasubramaniam S, Drabkin H, Gormaz JG, O'Sullivan C, Madan R, Fojo T. A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma. Oncologist 2017;22:888-e84. [PMID: 28679644 DOI: 10.1634/theoncologist.2017-0211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
447 Grünwald V, Seidel C, Fenner M, Ganser A, Busch J, Weikert S. Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br J Cancer 2011;105:1635-9. [PMID: 22033275 DOI: 10.1038/bjc.2011.389] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
448 Voss MH, Molina AM, Motzer RJ. mTOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am 2011;25:835-52. [PMID: 21763970 DOI: 10.1016/j.hoc.2011.04.008] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 7.5] [Reference Citation Analysis]
449 Eikesdal HP, Sugimoto H, Birrane G, Maeshima Y, Cooke VG, Kieran M, Kalluri R. Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity. Proc Natl Acad Sci U S A 2008;105:15040-5. [PMID: 18818312 DOI: 10.1073/pnas.0807055105] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
450 Schönberger T, Fandrey J, Prost-Fingerle K. Ways into Understanding HIF Inhibition. Cancers (Basel) 2021;13:E159. [PMID: 33466454 DOI: 10.3390/cancers13010159] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
451 Zhou X, Hou W, Gao L, Shui L, Yi C, Zhu H. Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality. Front Oncol 2020;10:1321. [PMID: 32850419 DOI: 10.3389/fonc.2020.01321] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
452 Quiroga Matamoros W, Fernandez F, Citarella Otero D, Rangel J, Estrada Guerrero A, Patiño ID. Guía de manejo del carcinoma de células renales. Urología Colombiana 2016;25:169-89. [DOI: 10.1016/j.uroco.2016.03.002] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
453 Hwang C, Heath EI. Angiogenesis inhibitors in the treatment of prostate cancer. J Hematol Oncol 2010;3:26. [PMID: 20678204 DOI: 10.1186/1756-8722-3-26] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
454 Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl. 2013;11:172-191. [PMID: 26217127 DOI: 10.1016/j.ejcsup.2013.07.016] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 9.1] [Reference Citation Analysis]
455 Agostino NM, Gingrich R, Drabick JJ. Bevacizumab demonstrates prolonged disease stabilization in patients with heavily pretreated metastatic renal cell carcinoma: a case series and review of the literature. Adv Urol 2010:687043. [PMID: 20721275 DOI: 10.1155/2010/687043] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
456 Khan MI, Sobocińska AA, Brodaczewska KK, Zielniok K, Gajewska M, Kieda C, Czarnecka AM, Szczylik C. Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212-2 in renal cell carcinoma. BMC Cancer 2018;18:583. [PMID: 29792186 DOI: 10.1186/s12885-018-4496-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
457 Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN Jr, Harzstark AL, Wagle N, Figlin RA, Smith GW, Garraway LA, Choueiri T, Erlandsson F, Laber DA. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New Drugs 2014;32:178-87. [PMID: 24242861 DOI: 10.1007/s10637-013-0045-6] [Cited by in Crossref: 182] [Cited by in F6Publishing: 175] [Article Influence: 20.2] [Reference Citation Analysis]
458 Brandes AA, Bartolotti M, Tosoni A, Poggi R, Franceschi E. Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist 2015;20:166-75. [PMID: 25568148 DOI: 10.1634/theoncologist.2014-0330] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
459 Crane CH, Winter K, Regine WF, Safran H, Rich TA, Curran W, Wolff RA, Willett CG. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol. 2009;27:4096-4102. [PMID: 19636002 DOI: 10.1200/jco.2009.21.8529] [Cited by in Crossref: 96] [Cited by in F6Publishing: 46] [Article Influence: 7.4] [Reference Citation Analysis]
460 Schepisi G, Conteduca V, Casadei C, Gurioli G, Rossi L, Gallà V, Cursano MC, Brighi N, Lolli C, Menna C, Farolfi A, Burgio SL, Altavilla A, Martinelli G, De Giorgi U. Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors. Front Oncol 2020;10:565857. [PMID: 33072597 DOI: 10.3389/fonc.2020.565857] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
461 Tripathi A, Drake CG, Harshman LC. Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. BioDrugs 2014;28:513-26. [PMID: 25445176 DOI: 10.1007/s40259-014-0111-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
462 van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Boven E. Targeted therapies in renal cell cancer: recent developments in imaging. Target Oncol. 2010;5:95-112. [PMID: 20625845 DOI: 10.1007/s11523-010-0146-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
463 Bamias A, Escudier B, Sternberg CN, Zagouri F, Dellis A, Djavan B, Tzannis K, Kontovinis L, Stravodimos K, Papatsoris A, Mitropoulos D, Deliveliotis C, Dimopoulos MA, Constantinides CA. Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation. Oncologist. 2017;22:667-679. [PMID: 28592625 DOI: 10.1634/theoncologist.2016-0435] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 8.2] [Reference Citation Analysis]
464 Harshman LC, Srinivas S. The bevacizumab experience in advanced renal cell carcinoma. Onco Targets Ther 2010;3:179-89. [PMID: 21049084 DOI: 10.2147/ott.s8157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
465 Yang J, Liu R, Ektare V, Stephens J, Shelbaya A. Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives. Appl Health Econ Health Policy 2021;19:605-18. [PMID: 33506318 DOI: 10.1007/s40258-021-00637-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
466 Sun M, Larcher A, Karakiewicz PI. Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence. Int J Nephrol Renovasc Dis 2014;7:401-7. [PMID: 25378943 DOI: 10.2147/IJNRD.S48496] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
467 Wang H, Chen X, Zhao J, Kang M, Dong R, Wang K, Qu Y. Predictive Nomogram for Midterm to Long-Term Prognosis in Patients with Papillary Renal Cell Carcinoma Based on Data from the Surveillance, Epidemiology, and End Results (SEER) Program. Med Sci Monit 2020;26:e921859. [PMID: 32570266 DOI: 10.12659/MSM.921859] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
468 Lambea J, Anido U, Etxániz O, Flores L, Montesa Á, Sepúlveda JM, Esteban E. The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma. Curr Oncol Rep 2016;18:66. [PMID: 27613167 DOI: 10.1007/s11912-016-0553-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
469 Furuse M, Kawabata S, Kuroiwa T, Miyatake S. Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. J Neurooncol 2011;102:471-5. [PMID: 20694573 DOI: 10.1007/s11060-010-0333-3] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 5.1] [Reference Citation Analysis]
470 Hemminki O, Perlis N, Bjorklund J, Finelli A, Zlotta AR, Hemminki A. Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not. Eur Urol Open Sci 2020;22:61-73. [PMID: 34337479 DOI: 10.1016/j.euros.2020.11.003] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
471 Saavedra E, Hollebecque A, Soria JC, Hartl DM. Dysphonia induced by anti-angiogenic compounds. Invest New Drugs 2014;32:774-82. [PMID: 24343672 DOI: 10.1007/s10637-013-0049-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
472 Kothari N, Almhanna K. Current status of novel agents in advanced gastroesophageal adenocarcinoma. J Gastrointest Oncol. 2015;6:60-74. [PMID: 25642339 DOI: 10.3978/j.issn.2078-6891.2014.098] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
473 Quivy A, Daste A, Harbaoui A, Duc S, Bernhard JC, Gross-Goupil M, Ravaud A. Optimal management of renal cell carcinoma in the elderly: a review. Clin Interv Aging 2013;8:433-42. [PMID: 23626463 DOI: 10.2147/CIA.S30765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
474 Matsushita H, Kakimi K, Tomita Y, Tatsugami K, Naito S, Suekane S, Noguchi M, Moriya F, Matsuoka K, Itoh K, Kobayashi H, Eto M, Takahashi W, Kawano Y, Wada Y. Exploring immune therapy for renal cancer. Int J Urol 2011;18:412-21. [PMID: 21599759 DOI: 10.1111/j.1442-2042.2011.02762.x] [Reference Citation Analysis]
475 Pouessel D, Patard J-, Culine S. Stratégie de la prise en charge médicale dans les stades métastatiques. Oncologie 2009;11:278-84. [DOI: 10.1007/s10269-009-1063-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
476 Aprile G, Bonotto M, Ongaro E, Pozzo C, Giuliani F. Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use. Drugs. 2013;73:2003-2015. [PMID: 24277700 DOI: 10.1007/s40265-013-0154-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
477 Cosmai L, Gallieni M, Liguigli W, Porta C. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). J Nephrol 2017;30:171-80. [PMID: 27154025 DOI: 10.1007/s40620-016-0311-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
478 Sun C, Li HL, Chen HR, Shi ML, Liu QH, Pan ZQ, Bai J, Zheng JN. Decreased expression of CHIP leads to increased angiogenesis via VEGF-VEGFR2 pathway and poor prognosis in human renal cell carcinoma. Sci Rep 2015;5:9774. [PMID: 26021863 DOI: 10.1038/srep09774] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
479 Staehler M, Haseke N, Khoder W, Stief CG. Profile of temsirolimus in the treatment of advanced renal cell carcinoma. Onco Targets Ther 2010;3:191-6. [PMID: 21049085 DOI: 10.2147/ott.s7657] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
480 Fiala O, Finek J, Poprach A, Melichar B, Kopecký J, Zemanova M, Kopeckova K, Mlcoch T, Dolezal T, Capkova L, Buchler T. Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients. Cancers (Basel) 2020;12:E808. [PMID: 32230921 DOI: 10.3390/cancers12040808] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
481 Greef B, Eisen T. Medical treatment of renal cancer: new horizons. Br J Cancer 2016;115:505-16. [PMID: 27490806 DOI: 10.1038/bjc.2016.230] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 7.5] [Reference Citation Analysis]
482 Bamias A, Karadimou A, Lampaki S, Lainakis G, Malettou L, Timotheadou E, Papazisis K, Andreadis C, Kontovinis L, Anastasiou I, Stravodimos K, Xanthakis I, Skolarikos A, Christodoulou C, Syrigos K, Papandreou C, Razi E, Dafni U, Fountzilas G, Dimopoulos MA. Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model. BMC Cancer 2010;10:45. [PMID: 20163744 DOI: 10.1186/1471-2407-10-45] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
483 Roviello G, Polom K, Petrioli R, Marano L, Marrelli D, Paganini G, Savelli V, Generali D, De Franco L, Ravelli A, Roviello F. Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. Tumour Biol 2016;37:127-40. [PMID: 26566626 DOI: 10.1007/s13277-015-4408-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
484 Yamasaki T, Kamba T, Kanno T, Inoue T, Shibasaki N, Arakaki R, Yamada T, Kondo K, Kamoto T, Nishiyama H, Ogawa O, Nakamura E. Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy. Cancer Sci 2012;103:2027-37. [PMID: 22931246 DOI: 10.1111/j.1349-7006.2012.02412.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
485 Escudier B, Szczylik C, Porta C, Gore M. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol 2012;9:327-37. [PMID: 22473096 DOI: 10.1038/nrclinonc.2012.59] [Cited by in Crossref: 88] [Cited by in F6Publishing: 88] [Article Influence: 8.8] [Reference Citation Analysis]
486 Woodrum C, Nobil A, Dabora SL. Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. J Transl Med. 2010;8:14. [PMID: 20146790 DOI: 10.1186/1479-5876-8-14] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
487 Kamrava M, Bernstein MB, Camphausen K, Hodge JW. Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination? Mol Biosyst 2009;5:1262-70. [PMID: 19823740 DOI: 10.1039/b911313b] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
488 Flippot R, Escudier B, Albiges L. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma. Drugs 2018;78:1443-57. [PMID: 30187355 DOI: 10.1007/s40265-018-0970-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
489 Mascarenhas L, Chi YY, Hingorani P, Anderson JR, Lyden ER, Rodeberg DA, Indelicato DJ, Kao SC, Dasgupta R, Spunt SL, Meyer WH, Hawkins DS. Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group. J Clin Oncol 2019;37:2866-74. [PMID: 31513481 DOI: 10.1200/JCO.19.00576] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
490 Sun M, Bianchi M, Hansen J, Trinh QD, Karakiewicz PI. Proof of efficacy is not enough: contemporary management of patients with metastatic renal cell carcinoma with targeted therapy. J Clin Oncol 2012;30:3901; author reply 3902. [PMID: 22987077 DOI: 10.1200/JCO.2012.43.7376] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
491 Flaherty KT. Where does the combination of sorafenib and interferon in renal cell carcinoma stand? Cancer 2010;116:4-7. [PMID: 19890962 DOI: 10.1002/cncr.24688] [Reference Citation Analysis]
492 Wang L, Ma L, Wang X, Li B, Guo S, Qiao Q. Therapeutic effects and associated adverse events of first-line treatments of advanced renal cell carcinoma (RCC): a meta-analysis. Int Urol Nephrol 2015;47:617-24. [PMID: 25686740 DOI: 10.1007/s11255-015-0932-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
493 Dorff TB, Goldkorn A, Quinn DI. Targeted therapy in renal cancer. Ther Adv Med Oncol 2009;1:183-205. [PMID: 21789121 DOI: 10.1177/1758834009349119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
494 Jordan EJ, Iyer G. Targeted therapy in advanced bladder cancer: what have we learned? Urol Clin North Am 2015;42:253-62, ix. [PMID: 25882566 DOI: 10.1016/j.ucl.2015.01.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
495 Grünwald V, Merseburger AS. Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment. Onco Targets Ther 2012;5:111-7. [PMID: 22787405 DOI: 10.2147/OTT.S23273] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
496 Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, Denker M, Leveque V, Cañamero M, Babitski G, Koeppen H, Ziai J, Sharma N, Gaire F, Chen DS, Waterkamp D, Hegde PS, McDermott DF. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun 2016;7:12624. [PMID: 27571927 DOI: 10.1038/ncomms12624] [Cited by in Crossref: 316] [Cited by in F6Publishing: 299] [Article Influence: 52.7] [Reference Citation Analysis]
497 Labriola MK, Batich KA, Zhu J, McNamara MA, Harrison MR, Armstrong AJ, George DJ, Zhang T. Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma. Clin Genitourin Cancer 2019;17:e513-21. [PMID: 30858035 DOI: 10.1016/j.clgc.2019.01.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
498 Morin E, Lindskog C, Johansson M, Egevad L, Sandström P, Harmenberg U, Claesson-Welsh L, Sjöberg E. Perivascular Neuropilin-1 expression is an independent marker of improved survival in renal cell carcinoma. J Pathol 2020;250:387-96. [PMID: 31880322 DOI: 10.1002/path.5380] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
499 Blank CU, Wong DJ, Ho TH, Bauer TM, Lee CB, Bene-Tchaleu F, Zhu J, Zhang X, Cha E, Sznol M. Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors. Curr Oncol 2021;28:5466-79. [PMID: 34940094 DOI: 10.3390/curroncol28060455] [Reference Citation Analysis]
500 Ladoire S, Bonnetain F, Gauthier M, Zanetta S, Petit JM, Guiu S, Kermarrec I, Mourey E, Michel F, Krause D, Hillon P, Cormier L, Ghiringhelli F, Guiu B. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents. Oncologist 2011;16:71-81. [PMID: 21212435 DOI: 10.1634/theoncologist.2010-0227] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 6.8] [Reference Citation Analysis]
501 Zaffuto E, Karakiewicz PI, Capitanio U. Complete response after treatment with first-line targeted anti-vascular endothelial growth factor therapy in metastatic renal cancer: what next? Ann Transl Med 2016;4:291. [PMID: 27568482 DOI: 10.21037/atm.2016.06.25] [Reference Citation Analysis]
502 Seitlinger J, Prieto M, Siat J, Renaud S. Pulmonary metastasectomy in renal cell carcinoma: a mainstay of multidisciplinary treatment. J Thorac Dis 2021;13:2636-42. [PMID: 34012612 DOI: 10.21037/jtd-2019-pm-10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
503 Dietz S, Sültmann H, Du Y, Reisinger E, Riediger AL, Volckmar AL, Stenzinger A, Schlesner M, Jäger D, Hohenfellner M, Duensing S, Grüllich C, Pahernik S. Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy. Oncotarget 2017;8:74049-57. [PMID: 29088767 DOI: 10.18632/oncotarget.18200] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
504 Fléchon A, Boyle H, Négrier S. [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma]. Bull Cancer 2010;97:73-82. [PMID: 20418206 DOI: 10.1684/bdc.2010.1072] [Reference Citation Analysis]
505 Reiter MA, Kurosch M, Haferkamp A. [Renal cell carcinoma: Drug therapy and prognostic models]. Urologe A 2015;54:735-46; quiz 747-8. [PMID: 25987339 DOI: 10.1007/s00120-015-3845-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
506 Ashouri K, Mohseni S, Tourtelot J, Sharma P, Spiess PE. Implications of Von Hippel-Lindau Syndrome and Renal Cell Carcinoma. J Kidney Cancer VHL 2015;2:163-73. [PMID: 28326271 DOI: 10.15586/jkcvhl.2015.41] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
507 Chang X, Zhang F, Liu T, Yang R, Ji C, Zhao X, Xu L, Liu G, Guo H. Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs. Oncotarget 2016;7:15801-10. [PMID: 26908455 DOI: 10.18632/oncotarget.7511] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
508 Akino T, Hida K, Hida Y, Tsuchiya K, Freedman D, Muraki C, Ohga N, Matsuda K, Akiyama K, Harabayashi T, Shinohara N, Nonomura K, Klagsbrun M, Shindoh M. Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am J Pathol 2009;175:2657-67. [PMID: 19875502 DOI: 10.2353/ajpath.2009.090202] [Cited by in Crossref: 134] [Cited by in F6Publishing: 125] [Article Influence: 10.3] [Reference Citation Analysis]
509 Cheng T, Wang L, Li Y, Huang C, Zeng L, Yang J. Differential microRNA expression in renal cell carcinoma. Oncol Lett 2013;6:769-76. [PMID: 24137408 DOI: 10.3892/ol.2013.1460] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
510 Dawsey SJ, Ornstein MC. Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma. Curr Oncol 2021;28:5019-24. [PMID: 34940060 DOI: 10.3390/curroncol28060421] [Reference Citation Analysis]
511 Frascà GM, Sandrini S, Cosmai L, Porta C, Asch W, Santoni M, Salviani C, D'Errico A, Malvi D, Balestra E, Gallieni M. Renal cancer in kidney transplanted patients. J Nephrol 2015;28:659-68. [PMID: 26202137 DOI: 10.1007/s40620-015-0219-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
512 Rossari JR, Metzger-Filho O, Paesmans M, Saini KS, Gennari A, de Azambuja E, Piccart-Gebhart M. Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence. J Oncol 2012;2012:417673. [PMID: 23008712 DOI: 10.1155/2012/417673] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 5.0] [Reference Citation Analysis]
513 Mariucci S, Rovati B, Manzoni M, Della Porta MG, Comolli G, Delfanti S, Danova M. Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors. Clin Exp Med 2011;11:199-210. [PMID: 21161672 DOI: 10.1007/s10238-010-0120-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
514 Higenell V, Fajzel R, Batist G, Cheema PK, McArthur HL, Melosky B, Morris D, Petrella TM, Sangha R, Savard MF, Sridhar SS, Stagg J, Stewart DJ, Verma S. A network approach to developing immuno-oncology combinations in Canada. Curr Oncol 2019;26:73-9. [PMID: 31043804 DOI: 10.3747/co.26.4393] [Reference Citation Analysis]
515 Bhome R, Al Saihati HA, Goh RW, Bullock MD, Primrose JN, Thomas GJ, Sayan AE, Mirnezami AH. Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside. New Horiz Transl Med 2016;3:9-21. [PMID: 27275004 DOI: 10.1016/j.nhtm.2016.03.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
516 Zhang F, Zhao G, Wu P, An Q, Yang Y, Chen X, Wang J, Wei D. Asynchronous abdominal wall and sigmoid metastases in clear cell renal cell carcinoma: A case report and literature review. Asian J Urol 2019;6:210-4. [PMID: 31061809 DOI: 10.1016/j.ajur.2018.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
517 Park K, Lee JL, Park I, Park S, Ahn Y, Ahn JH, Ahn S, Song C, Hong JH, Kim CS, Ahn H. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI. Med Oncol 2012;29:3291-7. [PMID: 22460837 DOI: 10.1007/s12032-012-0227-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
518 Clark DJ, Dhanasekaran SM, Petralia F, Pan J, Song X, Hu Y, da Veiga Leprevost F, Reva B, Lih TM, Chang HY, Ma W, Huang C, Ricketts CJ, Chen L, Krek A, Li Y, Rykunov D, Li QK, Chen LS, Ozbek U, Vasaikar S, Wu Y, Yoo S, Chowdhury S, Wyczalkowski MA, Ji J, Schnaubelt M, Kong A, Sethuraman S, Avtonomov DM, Ao M, Colaprico A, Cao S, Cho KC, Kalayci S, Ma S, Liu W, Ruggles K, Calinawan A, Gümüş ZH, Geiszler D, Kawaler E, Teo GC, Wen B, Zhang Y, Keegan S, Li K, Chen F, Edwards N, Pierorazio PM, Chen XS, Pavlovich CP, Hakimi AA, Brominski G, Hsieh JJ, Antczak A, Omelchenko T, Lubinski J, Wiznerowicz M, Linehan WM, Kinsinger CR, Thiagarajan M, Boja ES, Mesri M, Hiltke T, Robles AI, Rodriguez H, Qian J, Fenyö D, Zhang B, Ding L, Schadt E, Chinnaiyan AM, Zhang Z, Omenn GS, Cieslik M, Chan DW, Nesvizhskii AI, Wang P, Zhang H; Clinical Proteomic Tumor Analysis Consortium. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell 2019;179:964-983.e31. [PMID: 31675502 DOI: 10.1016/j.cell.2019.10.007] [Cited by in Crossref: 111] [Cited by in F6Publishing: 111] [Article Influence: 55.5] [Reference Citation Analysis]
519 Titz B, Kozak KR, Jeraj R. Computational modelling of anti-angiogenic therapies based on multiparametric molecular imaging data. Phys Med Biol 2012;57:6079-101. [PMID: 22972469 DOI: 10.1088/0031-9155/57/19/6079] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
520 Tykodi SS. PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. Onco Targets Ther. 2014;7:1349-1359. [PMID: 25114573 DOI: 10.2147/OTT.S48443] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
521 Gil-Gil MJ, Mesia C, Rey M, Bruna J. Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol 2013;7:123-35. [PMID: 23843722 DOI: 10.4137/CMO.S8503] [Cited by in Crossref: 42] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
522 McCormick B, Meissner MA, Karam JA, Wood CG. Surgical Complications of Presurgical Systemic Therapy for Renal Cell Carcinoma: A Systematic Review. Kidney Cancer 2017;1:115-21. [PMID: 30334013 DOI: 10.3233/KCA-170016] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
523 Zhu X, Tian X, Yu C, Hong J, Fang J, Chen H. Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials. Medicine (Baltimore) 2016;95:e4232. [PMID: 27559943 DOI: 10.1097/MD.0000000000004232] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
524 Zhang B, Malouf J, Young P, Kohli M, Dronca R. Cardiac Metastasis in Renal Cell Carcinoma without Vena Cava or Atrial Involvement: an Unusual Presentation of Metastatic Disease. Rare Tumors 2013;5:e29. [PMID: 24179641 DOI: 10.4081/rt.2013.e29] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
525 O'Hare T, McDermott R, Hannon R. Late anastomotic breakdown with bevacizumab in colorectal cancers, a case-based review. Ir J Med Sci 2018;187:333-6. [PMID: 28852961 DOI: 10.1007/s11845-017-1676-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
526 Cetin B, Afsar B, Deger SM, Gonul II, Gumusay O, Ozet A, Benekli M, Coskun U, Buyukberber S. Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma. Int Urol Nephrol 2014;46:1081-7. [PMID: 24307427 DOI: 10.1007/s11255-013-0613-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
527 Schmidt S, Kunath F, Kroeger N. [Immunotherapy for advanced renal cell cancer]. Urologe A 2015;54:716-20. [PMID: 25987336 DOI: 10.1007/s00120-015-3825-0] [Reference Citation Analysis]
528 Lu J, Zhu L, Zheng LP, Cui Q, Zhu HH, Zhao H, Shen ZJ, Dong HY, Chen SS, Wu WZ, Tan JM. Overexpression of ULK1 Represents a Potential Diagnostic Marker for Clear Cell Renal Carcinoma and the Antitumor Effects of SBI-0206965. EBioMedicine 2018;34:85-93. [PMID: 30078736 DOI: 10.1016/j.ebiom.2018.07.034] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
529 Díaz-Montero CM, Rini BI, Finke JH. The immunology of renal cell carcinoma. Nat Rev Nephrol 2020;16:721-35. [PMID: 32733094 DOI: 10.1038/s41581-020-0316-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
530 Ghiaseddin A, Peters KB. Use of bevacizumab in recurrent glioblastoma. CNS Oncol 2015;4:157-69. [PMID: 25906439 DOI: 10.2217/cns.15.8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
531 Wu Y, Mao F, Zuo X, Moussalli MJ, Elias E, Xu W, Shureiqi I. 15-LOX-1 suppression of hypoxia-induced metastatic phenotype and HIF-1α expression in human colon cancer cells. Cancer Med. 2014;3:472-484. [PMID: 24634093 DOI: 10.1002/cam4.222] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
532 Garcia A, Singh H. Bevacizumab and ovarian cancer. Ther Adv Med Oncol 2013;5:133-41. [PMID: 23450196 DOI: 10.1177/1758834012467661] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
533 Ahmadizar F, Onland-Moret NC, de Boer A, Liu G, Maitland-van der Zee AH. Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One 2015;10:e0136324. [PMID: 26331473 DOI: 10.1371/journal.pone.0136324] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
534 Shen C, Kaelin WG. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol. 2013;23:18-25. [PMID: 22705278 DOI: 10.1016/j.semcancer.2012.06.001] [Cited by in Crossref: 210] [Cited by in F6Publishing: 200] [Article Influence: 21.0] [Reference Citation Analysis]
535 Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR. Antiangiogenic therapy for cancer: an update. Pharmacotherapy 2012;32:1095-111. [PMID: 23208836 DOI: 10.1002/phar.1147] [Cited by in Crossref: 120] [Cited by in F6Publishing: 98] [Article Influence: 13.3] [Reference Citation Analysis]
536 Chen H, Zhu D, Zheng Z, Cai Y, Chen Z, Xie W. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway. Clin Transl Oncol 2019;21:939-49. [PMID: 30607788 DOI: 10.1007/s12094-018-02012-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
537 Adler MJ, Dimitrov DS. Therapeutic antibodies against cancer. Hematol Oncol Clin North Am 2012;26:447-81, vii. [PMID: 22520975 DOI: 10.1016/j.hoc.2012.02.013] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 5.3] [Reference Citation Analysis]
538 Diaz D, Chara L, Chevarria J, Carballido J, Esteban E, Navas V, Monserrat J, Prieto A, de la Hera A, Alvarez-Mon M. Inhaled IL-2 induces systemic immunomodulation in patients with renal cell carcinoma and lung metastasis. Cancer Immunol Immunother 2009;58:235-45. [PMID: 18592236 DOI: 10.1007/s00262-008-0546-x] [Reference Citation Analysis]
539 Ghosn M, Eid R, Hamada E, Abdel Azim H, Zekri J, Al-Mansour M, Jaloudi M, Nasr F, Errihani H, Bounedjar A, Mezlini A, Boussen H, Kattan J, El Karak F, Farhat F; Africa Middle East Cancer Intergroup. OSSMAR: An Observational Study to Describe the Use of Sunitinib in Real-Life Practice for the Treatment of Metastatic Renal Cell Carcinoma. J Glob Oncol 2019;5:1-10. [PMID: 31657977 DOI: 10.1200/JGO.18.00238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
540 Duran I, Lambea J, Maroto P, González-Larriba JL, Flores L, Granados-Principal S, Graupera M, Sáez B, Vivancos A, Casanovas O. Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action. Target Oncol 2017;12:19-35. [PMID: 27844272 DOI: 10.1007/s11523-016-0463-4] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 9.0] [Reference Citation Analysis]
541 Ke J, Chen J, Liu X. Analyzing and validating the prognostic value and immune microenvironment of clear cell renal cell carcinoma. Animal Cells and Systems. [DOI: 10.1080/19768354.2022.2056635] [Reference Citation Analysis]
542 Lin E, Liu X, Liu Y, Zhang Z, Xie L, Tian K, Liu J, Yu Y. Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma. Front Immunol 2021;12:653358. [PMID: 33746989 DOI: 10.3389/fimmu.2021.653358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
543 Li L, Kaelin WG Jr. New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am 2011;25:667-86. [PMID: 21763962 DOI: 10.1016/j.hoc.2011.04.004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 4.6] [Reference Citation Analysis]
544 Chittoria N, Haddad H, Elson P, Tannir NM, Wood LS, Dreicer R, Garcia JA, Rini BI, Jonasch E. Response to post-axitinib treatment in patients with metastatic renal cell carcinoma. BMC Cancer 2016;16:254. [PMID: 27026229 DOI: 10.1186/s12885-016-2282-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
545 Gauler T, Schuler M. [Can systemic treatment for lymph node metastases be given with curative intent?]. Urologe A 2009;48:62-5. [PMID: 19050846 DOI: 10.1007/s00120-008-1763-9] [Reference Citation Analysis]
546 Flaherty KT, Lee SJ, Zhao F, Schuchter LM, Flaherty L, Kefford R, Atkins MB, Leming P, Kirkwood JM. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol 2013;31:373-9. [PMID: 23248256 DOI: 10.1200/JCO.2012.42.1529] [Cited by in Crossref: 149] [Cited by in F6Publishing: 50] [Article Influence: 14.9] [Reference Citation Analysis]
547 Donini M, Buti S, Lazzarelli S, Bozzetti R, Rivoltini L, Camisaschi C, Castelli C, Bearz A, Simonelli C, Lo Re G, Mattioli R, Caminiti C, Passalacqua R; GOIRC (Italian Oncology Group for Clinical Research). Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg). Target Oncol 2015;10:277-86. [PMID: 25230695 DOI: 10.1007/s11523-014-0337-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
548 Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6:465-477. [PMID: 19581909 DOI: 10.1038/nrclinonc.2009.94] [Cited by in Crossref: 340] [Cited by in F6Publishing: 301] [Article Influence: 26.2] [Reference Citation Analysis]
549 Fan F, Schimming A, Jaeger D, Podar K. Targeting the tumor microenvironment: focus on angiogenesis. J Oncol 2012;2012:281261. [PMID: 21876693 DOI: 10.1155/2012/281261] [Cited by in Crossref: 53] [Cited by in F6Publishing: 61] [Article Influence: 4.8] [Reference Citation Analysis]
550 Seruga B, Gan HK, Knox JJ. Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer. Curr Oncol 2009;16 Suppl 1:S52-9. [PMID: 19478903 DOI: 10.3747/co.v16i0.402] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
551 Bender RJ, Mac Gabhann F. Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer. PLoS One. 2013;8:e61788. [PMID: 23667446 DOI: 10.1371/journal.pone.0061788] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
552 Di Salvatore M, Orlandi A, Bagalà C, Quirino M, Cassano A, Astone A, Barone C. Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Prolif 2011;44:139-46. [PMID: 21401755 DOI: 10.1111/j.1365-2184.2011.00745.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
553 Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28:2137-2143. [PMID: 20368558 DOI: 10.1200/jco.2009.26.5561] [Cited by in Crossref: 580] [Cited by in F6Publishing: 245] [Article Influence: 48.3] [Reference Citation Analysis]
554 North SA, Basappa N, Basiuk J, Bjarnason G, Breau R, Canil C, Heng D, Jewett MA, Kapoor A, Kollmannsberger C, Potvin K, Neil Reaume M, Dean Ruether J, Venner P, Wood L; Canadian Kidney Cancer Forum 2015. Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. Can Urol Assoc J 2015;9:164-70. [PMID: 26225164 DOI: 10.5489/cuaj.2894] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
555 Sun X, Gan L, Na A, Ge L, Chen B, Liu J. Combination with Stereotactic Body Radiotherapy Offers a Promising Strategy to Overcome Resistance to Immunotherapy in Advanced Renal Cell Cancer. J Oncol 2019;2019:1483406. [PMID: 31871454 DOI: 10.1155/2019/1483406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
556 Fisher R, Larkin J, Swanton C. Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. EPMA J 2011;3:1. [PMID: 22738081 DOI: 10.1007/s13167-011-0137-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
557 Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel KK, Matin SF, Wood CG, Tannir NM. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol 2011;22:1048-53. [PMID: 21115604 DOI: 10.1093/annonc/mdq563] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
558 Fendler JP, Malavaud B, Gimel P, Duclos B, Chevreau C, Pignot G. [Renal cell carcinoma: antiangiogenic therapies and management of the complications. A case report]. Prog Urol 2010;20 Suppl 1:S27-32. [PMID: 20493440 DOI: 10.1016/S1166-7087(10)70022-1] [Reference Citation Analysis]
559 Gross-Goupil M, François L, Quivy A, Ravaud A. Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. Clin Med Insights Oncol 2013;7:269-77. [PMID: 24250243 DOI: 10.4137/CMO.S10594] [Cited by in Crossref: 44] [Cited by in F6Publishing: 20] [Article Influence: 4.9] [Reference Citation Analysis]
560 Biró K, Küronya Z. [Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines]. Magy Onkol 2010;54:369-76. [PMID: 21163768 DOI: 10.1556/MOnkol.54.2010.4.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
561 George S, Bukowski RM. Role of everolimus in the treatment of renal cell carcinoma. Ther Clin Risk Manag 2009;5:699-706. [PMID: 19774211 DOI: 10.2147/tcrm.s4895] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
562 Nuijten M, Mickisch G. SUN vs BEVthornIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival. Br J Cancer 2010;102:232-3; author reply 234-5. [PMID: 20051962 DOI: 10.1038/sj.bjc.6605446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
563 Lin R, Huang J, Wang L, Li Y, Lipowska M, Wu H, Yang J, Mao H. Bevacizumab and near infrared probe conjugated iron oxide nanoparticles for vascular endothelial growth factor targeted MR and optical imaging. Biomater Sci 2018;6:1517-25. [PMID: 29652061 DOI: 10.1039/c8bm00225h] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
564 Garje R, An JJ, Sanchez K, Greco A, Stolwijk J, Devor E, Rustum Y, Zakharia Y. Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment. Int J Mol Sci 2018;19:E3834. [PMID: 30513765 DOI: 10.3390/ijms19123834] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
565 Bensalah K, Bigot P, Albiges L, Bernhard J, Bodin T, Boissier R, Correas J, Gimel P, Hetet J, Long J, Nouhaud F, Ouzaïd I, Rioux-leclercq N, Méjean A. Recommandations françaises du Comité de cancérologie de l’AFU – actualisation 2020–2022 : prise en charge du cancer du rein. Progrès en Urologie 2020;30:S2-S51. [DOI: 10.1016/s1166-7087(20)30749-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
566 Verzoni E, Grassi P, Testa I, Iacovelli R, Biondani P, Garanzini E, De Braud F, Procopio G. Targeted treatments in advanced renal cell carcinoma: focus on axitinib. Pharmgenomics Pers Med 2014;7:107-16. [PMID: 24715765 DOI: 10.2147/PGPM.S37098] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
567 Atkins MB. Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy. Med Oncol 2009;26 Suppl 1:18-22. [PMID: 19165638 DOI: 10.1007/s12032-008-9148-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
568 Vogl UM, Bojic M, Lamm W, Frischer JM, Pichelmayer O, Kramer G, Haitel A, Kitz K, Harmankaya K, Zielinski CC, Schmidinger M. Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma. BMC Cancer 2010;10:480. [PMID: 20819239 DOI: 10.1186/1471-2407-10-480] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
569 Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 2010;117:497-504. [PMID: 20363017 DOI: 10.1016/j.ygyno.2010.02.021] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 5.2] [Reference Citation Analysis]
570 Ralli M, Altissimi G, Turchetta R, Rigante M. Metastatic Renal Cell Carcinoma Presenting as a Paranasal Sinus Mass: The Importance of Differential Diagnosis. Case Rep Otolaryngol 2017;2017:9242374. [PMID: 28168075 DOI: 10.1155/2017/9242374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
571 Yanmaz MT, Guner SI, Satılmıs B, Akyol H, Aydın MA. Thirty-minutes infusion rate is safe enough for bevacizumab; no need for initial prolong infusion. Med Oncol 2014;31:276. [PMID: 25294426 DOI: 10.1007/s12032-014-0276-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
572 Li P, Jahnke J, Pettit AR, Wong YN, Doshi JA. Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma. JAMA Netw Open 2019;2:e195806. [PMID: 31199450 DOI: 10.1001/jamanetworkopen.2019.5806] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
573 Eichholz A, Merchant S, Gaya AM. Anti-angiogenesis therapies: their potential in cancer management. Onco Targets Ther 2010;3:69-82. [PMID: 20616958 DOI: 10.2147/ott.s5256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 22] [Article Influence: 0.1] [Reference Citation Analysis]
574 Gallardo E, Méndez-Vidal MJ, Pérez-Gracia JL, Sepúlveda-Sánchez JM, Campayo M, Chirivella-González I, García-Del-Muro X, González-Del-Alba A, Grande E, Suárez C. SEOM clinical guideline for treatment of kidney cancer (2017). Clin Transl Oncol 2018;20:47-56. [PMID: 29134564 DOI: 10.1007/s12094-017-1765-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
575 Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. [PMID: 28276433 DOI: 10.1038/nrdp.2017.9] [Cited by in Crossref: 616] [Cited by in F6Publishing: 675] [Article Influence: 123.2] [Reference Citation Analysis]
576 Akaza H, Oya M, Iijima M, Hyodo I, Gemma A, Itoh H, Adachi M, Okayama Y, Sunaya T, Inuyama L. A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance. Jpn J Clin Oncol 2015;45:953-62. [PMID: 26206897 DOI: 10.1093/jjco/hyv099] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
577 Singh A, Singh I, Singh N, Puzanov I. Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab. Onco Targets Ther 2020;13:4021-34. [PMID: 32494157 DOI: 10.2147/OTT.S215173] [Reference Citation Analysis]
578 Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, Choueiri TK, Coates A. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer. 2011;47:2706-2714. [PMID: 22078932 DOI: 10.1016/j.ejca.2011.09.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
579 Alsharm A, Bazarbashi S, Alghamdi A, Alkhateeb S, Aljubran A, Abusamra A, Alharbi H, Alotaibi M, Almansour M, Alkushi H, Ahmed I, Murshid E, Eltijani A, Rabah D. Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma 2017. Urol Ann 2018;10:123-32. [PMID: 29719321 DOI: 10.4103/UA.UA_175_17] [Reference Citation Analysis]
580 Yu SS, Quinn DI, Dorff TB. Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. Onco Targets Ther 2016;9:5825-37. [PMID: 27713636 DOI: 10.2147/OTT.S97397] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
581 Ringhoffer M, Rinnab L, Küfer R, Greiner J. [Systemic therapy of metastatic renal cell carcinoma: from many options to the therapeutic strategy]. Urologe A 2009;48:1308-17. [PMID: 19806342 DOI: 10.1007/s00120-009-2109-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
582 Ruiz-Morales JM, Heng DY. Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. Ther Adv Urol 2016;8:338-47. [PMID: 27904650 DOI: 10.1177/1756287216663073] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
583 Porta C, Paglino C, Imarisio I, Ganini C, Pedrazzoli P. Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? J Cancer 2011;2:333-8. [PMID: 21716852 DOI: 10.7150/jca.2.333] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
584 Pohl C, Polimeni M, Indrakumar S, Streicher W, Peters GHJ, Nørgaard A, Lund M, Harris P. Electrostatics Drive Oligomerization and Aggregation of Human Interferon Alpha-2a. J Phys Chem B 2021;125:13657-69. [PMID: 34898211 DOI: 10.1021/acs.jpcb.1c07090] [Reference Citation Analysis]
585 Bukowski RM. Targeted Therapies: Bevacizumab and interferon-alpha in metastatic renal-cell carcinoma. Nat Rev Clin Oncol 2009;6:253-4. [PMID: 19390549 DOI: 10.1038/nrclinonc.2009.45] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
586 Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, Desharnais J, Hagen C, Levin NJ, Shields MJ, Parish M, Murphy RE, Del Rosario J, Oates BD, Lai JY, Matin MJ, Ainekulu Z, Bhat A, Bradshaw CW, Woodnutt G, Lerner RA, Lappe RW. Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A 2010;107:22611-6. [PMID: 21149738 DOI: 10.1073/pnas.1016478108] [Cited by in Crossref: 99] [Cited by in F6Publishing: 82] [Article Influence: 8.3] [Reference Citation Analysis]
587 Jeldres C, Sun M, Perrotte P, Karakiewicz PI. Pazopanib trial data cannot support first-line use. Nat Rev Urol 2010;7:307-8. [PMID: 20535144 DOI: 10.1038/nrurol.2010.65] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
588 Garcia-Roig M, Ortiz N, Lokeshwar V. Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need? Curr Urol Rep 2014;15:375. [PMID: 24337833 DOI: 10.1007/s11934-013-0375-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
589 Hilmi C, Guyot M, Pagès G. VEGF spliced variants: possible role of anti-angiogenesis therapy. J Nucleic Acids 2012;2012:162692. [PMID: 22013509 DOI: 10.1155/2012/162692] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
590 Alldredge JK, Tewari KS. Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer. Oncologist 2016;21:576-85. [PMID: 27026677 DOI: 10.1634/theoncologist.2015-0393] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
591 Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32:760-767. [PMID: 24297950 DOI: 10.1200/jco.2013.50.3961] [Cited by in Crossref: 253] [Cited by in F6Publishing: 119] [Article Influence: 28.1] [Reference Citation Analysis]
592 Reynolds AR. Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose Response 2010;8:253-84. [PMID: 20877487 DOI: 10.2203/dose-response.09-049.Reynolds] [Cited by in Crossref: 64] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
593 Bhatt JR, Finelli A. Landmarks in the diagnosis and treatment of renal cell carcinoma. Nat Rev Urol 2014;11:517-25. [PMID: 25112856 DOI: 10.1038/nrurol.2014.194] [Cited by in Crossref: 105] [Cited by in F6Publishing: 116] [Article Influence: 13.1] [Reference Citation Analysis]
594 Liu K, Wang P, Zhu X, Bei Y, Zheng Z, Yan S. Disparities of age-based cancer-specific survival improvement with various clinicopathologic characteristics for kidney cancer. Cancer Manag Res 2018;10:2259-68. [PMID: 30100757 DOI: 10.2147/CMAR.S169192] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
595 Tykodi SS, Satoh S, Deming JD, Chou J, Harrop R, Warren EH. CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model. J Immunother 2012;35:523-33. [PMID: 22892449 DOI: 10.1097/CJI.0b013e318261d630] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
596 Eskander RN, Tewari KS. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. Future Oncol 2015;11:909-22. [PMID: 25760973 DOI: 10.2217/fon.14.276] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
597 Comandone A, Vana F, Comandone T, Tucci M. Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results. Cancers (Basel) 2021;13:5896. [PMID: 34885006 DOI: 10.3390/cancers13235896] [Reference Citation Analysis]
598 Cofano F, Monticelli M, Ajello M, Zenga F, Marengo N, Di Perna G, Altieri R, Cassoni P, Bertero L, Melcarne A, Tartara F, Ducati A, Garbossa D. The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases. Cancer Control 2019;26:1073274819870549. [PMID: 31865766 DOI: 10.1177/1073274819870549] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
599 Grassi P, Doucet L, Giglione P, Grünwald V, Melichar B, Galli L, De Giorgi U, Sabbatini R, Ortega C, Santoni M, Bamias A, Verzoni E, Derosa L, Studentova H, Pacifici M, Coppa J, Mazzaferro V, de Braud F, Porta C, Escudier B, Procopio G. Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. PLoS One 2016;11:e0151662. [PMID: 27064898 DOI: 10.1371/journal.pone.0151662] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
600 Ning S, Guo S, Xie J, Xu Y, Lu X, Chen Y. TROP2 correlates with microvessel density and poor prognosis in hilar cholangiocarcinoma. J Gastrointest Surg. 2013;17:360-368. [PMID: 23207686 DOI: 10.1007/s11605-012-2105-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
601 Hirsch BR, Burke JM, Agrawal M, Hauke RJ, Hutson TE, Doshi G, Fleming MT, Vogelzang NJ. Sequential Therapy in Metastatic Renal Cell Carcinoma. J Kidney Cancer VHL 2016;3:23-35. [PMID: 28326277 DOI: 10.15586/jkcvhl.2016.46] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
602 Choueiri M, Jonasch E. Have molecularly targeted therapies improved overall survival in renal cell carcinoma? Curr Oncol Rep 2011;13:153-6. [PMID: 21455732 DOI: 10.1007/s11912-011-0167-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
603 Bitting RL, Healy P, Creel PA, Turnbull J, Morris K, Wood SY, Hurwitz HI, Starr MD, Nixon AB, Armstrong AJ, George DJ. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2014;12:241-50. [PMID: 24685058 DOI: 10.1016/j.clgc.2013.11.020] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
604 García-Martínez E, Smith M, Buqué A, Aranda F, de la Peña FA, Ivars A, Cánovas MS, Conesa MAV, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. Oncoimmunology 2018;7:e1433982. [PMID: 29872569 DOI: 10.1080/2162402X.2018.1433982] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 6.3] [Reference Citation Analysis]
605 Thompson Coon JS, Liu Z, Hoyle M, Rogers G, Green C, Moxham T, Welch K, Stein K. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer 2009;101:238-43. [PMID: 19568242 DOI: 10.1038/sj.bjc.6605167] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
606 Ma X, Wang L, Li H, Zhang Y, Gao Y, Guo G, Liu K, Meng Q, Zhao C, Wang D, Song Z, Zhang X. Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer. Sci Rep 2016;6:30886. [PMID: 27488093 DOI: 10.1038/srep30886] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
607 Curtis SA, Cohen JV, Kluger HM. Evolving Immunotherapy Approaches for Renal Cell Carcinoma. Curr Oncol Rep 2016;18:57. [PMID: 27475806 DOI: 10.1007/s11912-016-0542-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
608 Montero AJ, Escobar M, Lopes G, Glück S, Vogel C. Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr Oncol Rep 2012;14:1-11. [PMID: 22012632 DOI: 10.1007/s11912-011-0202-z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 5.6] [Reference Citation Analysis]
609 Hofmann F, Hwang EC, Lam TB, Bex A, Yuan Y, Marconi LS, Ljungberg B. Targeted therapy for metastatic renal cell carcinoma. Cochrane Database Syst Rev 2020;10:CD012796. [PMID: 33058158 DOI: 10.1002/14651858.CD012796.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
610 Retz M, Gschwend JE, Lehmann J. [Systemic chemotherapy for bladder cancer: news in 2009]. Urologe A 2009;48:655-62. [PMID: 19557469 DOI: 10.1007/s00120-009-2021-5] [Reference Citation Analysis]
611 Shek D, Longmate J, Quinn DI, Margolin KA, Twardowski P, Gandara DR, Frankel P, Pan CX, Lara PN Jr. A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma. Int J Clin Oncol 2011;16:494-9. [PMID: 21431345 DOI: 10.1007/s10147-011-0212-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
612 Eskander RN, Tewari KS. Targeting angiogenesis in advanced cervical cancer. Ther Adv Med Oncol 2014;6:280-92. [PMID: 25364393 DOI: 10.1177/1758834014543794] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
613 Heudobler D, Rechenmacher M, Lüke F, Vogelhuber M, Klobuch S, Thomas S, Pukrop T, Hackl C, Herr W, Ghibelli L, Gerner C, Reichle A. Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis. Front Pharmacol 2018;9:1357. [PMID: 30546308 DOI: 10.3389/fphar.2018.01357] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
614 Wei C, Wang S, Ye Z, Chen Z. Efficacy of targeted therapy for advanced renal cell carcinoma: a systematic review and meta-analysis of randomized controlled trials. Int Braz J Urol 2018;44:219-37. [PMID: 29211397 DOI: 10.1590/S1677-5538.IBJU.2017.0315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
615 Aslam S, Eisen T. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell cancer: latest results and clinical implications. Ther Adv Med Oncol 2013;5:324-33. [PMID: 24179487 DOI: 10.1177/1758834013507966] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
616 Allard CB, Gelpi-Hammerschmidt F, Harshman LC, Choueiri TK, Faiena I, Modi P, Chung BI, Tinay I, Singer EA, Chang SL. Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States. Urol Oncol. 2015;33:496.e11-496.e16. [PMID: 26210683 DOI: 10.1016/j.urolonc.2015.06.014] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
617 Tykodi SS, Voong LN, Warren EH. Combining allogeneic immunotherapy with an mTOR inhibitor for advanced renal cell carcinoma. Bone Marrow Transplant 2010;45:1360-2. [PMID: 19966847 DOI: 10.1038/bmt.2009.338] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
618 Mohamed AF, Hauber AB, Neary MP. Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma. Pharmacoeconomics 2011;29:977-88. [PMID: 21854079 DOI: 10.2165/11593370-000000000-00000] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
619 Pombar-Gomez M, Lopez-Lopez E, Martin-Guerrero I, Garcia-Orad Carles A, de Pancorbo MM. Potential relationship between single nucleotide polymorphisms used in forensic genetics and diseases or other traits in European population. Int J Legal Med 2015;129:435-43. [PMID: 25763762 DOI: 10.1007/s00414-015-1165-7] [Reference Citation Analysis]
620 Upreti M, Koonce NA, Hennings L, Chambers TC, Griffin RJ. Pegylated IFN-α sensitizes melanoma cells to chemotherapy and causes premature senescence in endothelial cells by IRF-1 mediated signaling. Cell Death Dis 2010;1:e67. [PMID: 21197417 DOI: 10.1038/cddis.2010.43] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
621 Oh WK, McDermott D, Porta C, Levy A, Elaidi R, Scotte F, Hawkins R, Castellano D, Bellmunt J, Rha SY, Sun JM, Nathan P, Feinberg BA, Scott J, McDermott R, Ahn JH, Wagstaff J, Chang YH, Ou YC, Donnellan P, Huang CY, McCaffrey J, Chiang PH, Chuang CK, Korves C, Neary MP, Diaz JR, Mehmud F, Duh MS. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. Int J Oncol 2014;44:5-16. [PMID: 24247547 DOI: 10.3892/ijo.2013.2181] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
622 Tartari F, Conti A, Cerqueti R. Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials. PLoS One 2017;12:e0183639. [PMID: 28829823 DOI: 10.1371/journal.pone.0183639] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
623 Stewart DJ, Kurzrock R. Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer 2013;13:193. [PMID: 23587187 DOI: 10.1186/1471-2407-13-193] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
624 Raval SH, Singh RD, Joshi DV, Patel HB, Mody SK. Recent developments in receptor tyrosine kinases targeted anticancer therapy. Vet World 2016;9:80-90. [PMID: 27051190 DOI: 10.14202/vetworld.2016.80-90] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
625 Kerigh BF, Bahrami A, Shamsa A, Abolbashari M. Assessment of angiogenic factor, vascular endothelial growth factor, serum and urine level changes in superficial bladder tumor immunotherapy by intravesical Bacillus Calmette-Guerin. Urol Ann 2010;2:91-5. [PMID: 20981194 DOI: 10.4103/0974-7796.68855] [Reference Citation Analysis]
626 Wang M, Li X, Zhang J, Yang Q, Chen W, Jin W, Huang YR, Yang R, Gao WQ. AHNAK2 is a Novel Prognostic Marker and Oncogenic Protein for Clear Cell Renal Cell Carcinoma. Theranostics 2017;7:1100-13. [PMID: 28435451 DOI: 10.7150/thno.18198] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
627 Smith JL, Riedel RF. Emerging therapeutic targets for soft tissue sarcoma. Curr Oncol Rep 2011;13:350-8. [PMID: 21523334 DOI: 10.1007/s11912-011-0175-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
628 Dorff TB, Longmate JA, Pal SK, Stadler WM, Fishman MN, Vaishampayan UN, Rao A, Pinksi JK, Hu JS, Quinn DI, Lara PN Jr. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer 2017;123:4566-73. [PMID: 28832978 DOI: 10.1002/cncr.30942] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
629 Wang CJ, Tong PJ, Zhu MY. The combinational therapy of trastuzumab and cetuximab inhibits tumor growth in a patient-derived tumor xenograft model of gastric cancer. Clin Transl Oncol 2016;18:507-14. [PMID: 26370419 DOI: 10.1007/s12094-015-1397-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
630 Xiao B, Wang W, Zhang D. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. Onco Targets Ther 2018;11:5059-74. [PMID: 30174444 DOI: 10.2147/OTT.S166151] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
631 Shingarev R, Jaimes EA. Renal cell carcinoma: new insights and challenges for a clinician scientist. Am J Physiol Renal Physiol 2017;313:F145-54. [PMID: 28381462 DOI: 10.1152/ajprenal.00480.2016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
632 Gorenjak V, Vance DR, Dade S, Stathopoulou MG, Doherty L, Xie T, Murray H, Masson C, Lamont J, Fitzgerald P, Visvikis-Siest S. Epigenome-wide association study in healthy individuals identifies significant associations with DNA methylation and PBMC extract VEGF-A concentration. Clin Epigenetics 2020;12:79. [PMID: 32503626 DOI: 10.1186/s13148-020-00874-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
633 Kempkensteffen C, Fritzsche FR, Johannsen M, Weikert S, Hinz S, Dietel M, Riener MO, Moch H, Jung K, Krause H, Miller K, Kristiansen G. Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer. BMC Cancer 2009;9:276. [PMID: 19664236 DOI: 10.1186/1471-2407-9-276] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
634 Geiger-Gritsch S, Stollenwerk B, Miksad R, Guba B, Wild C, Siebert U. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist. 2010;15:1179-1191. [PMID: 21045188 DOI: 10.1634/theoncologist.2009-0155] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
635 Larkin JM, Kipps EL, Powell CJ, Swanton C. Systemic therapy for advanced renal cell carcinoma. Ther Adv Med Oncol 2009;1:15-27. [PMID: 21789110 DOI: 10.1177/1758834009338430] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
636 Lee CS, Cragg M, Glennie M, Johnson P. Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol. 2013;76:233-247. [PMID: 23701301 DOI: 10.1111/bcp.12164] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
637 Pooleri GK, Nair TB, Sanjeevan KV, Thomas A. Neo adjuvant treatment with targeted molecules for renal cell cancer in current clinical practise. Indian J Surg Oncol 2012;3:114-9. [PMID: 23730100 DOI: 10.1007/s13193-011-0100-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
638 Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Davis DW, Smith LA, Tannir NM, Gombos DS, Fuller GN, Matin SF. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol 2011;22:2661-6. [PMID: 22105611 DOI: 10.1093/annonc/mdr011] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 5.8] [Reference Citation Analysis]
639 Ambasta RK, Sharma A, Kumar P. Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy. Vasc Cell 2011;3:26. [PMID: 22082307 DOI: 10.1186/2045-824X-3-26] [Cited by in Crossref: 36] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
640 Pal SK, Quinn DI. Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev. 2013;39:709-719. [PMID: 23433636 DOI: 10.1016/j.ctrv.2012.12.015] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 5.7] [Reference Citation Analysis]
641 McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, Brahmer JR, Carvajal RD, Hammers HJ, Puzanov I, Hodi FS, Kluger HM, Topalian SL, Pardoll DM, Wigginton JM, Kollia GD, Gupta A, McDonald D, Sankar V, Sosman JA, Atkins MB. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol 2015;33:2013-20. [PMID: 25800770 DOI: 10.1200/JCO.2014.58.1041] [Cited by in Crossref: 300] [Cited by in F6Publishing: 171] [Article Influence: 42.9] [Reference Citation Analysis]
642 Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 2012;62:1013-9. [PMID: 22771265 DOI: 10.1016/j.eururo.2012.06.043] [Cited by in Crossref: 106] [Cited by in F6Publishing: 98] [Article Influence: 10.6] [Reference Citation Analysis]
643 Yu X, Wang B, Li X, Lin G, Zhang C, Yang Y, Fang D, Song Y, He Z, Zhou L. The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy. Biomed Res Int 2015;2015:176373. [PMID: 26568955 DOI: 10.1155/2015/176373] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
644 Wehland M, Bauer J, Magnusson NE, Infanger M, Grimm D. Biomarkers for anti-angiogenic therapy in cancer. Int J Mol Sci 2013;14:9338-64. [PMID: 23629668 DOI: 10.3390/ijms14059338] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
645 Guo G, Cai W, Li H, Gao J, Ma X, Dong J, Fu W, Zhang X. Presurgical neoadjuvant targeted molecular therapy for kidney cancer with concomitant vena cava tumor embolus: A clinical study. Oncol Lett 2017;14:369-75. [PMID: 28693178 DOI: 10.3892/ol.2017.6131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
646 Molina AM, Feldman DR, Voss MH, Ginsberg MS, Baum MS, Brocks DR, Fischer PM, Trinos MJ, Patil S, Motzer RJ. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2012;118:1868-76. [PMID: 21898375 DOI: 10.1002/cncr.26429] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 7.5] [Reference Citation Analysis]
647 Venur VA, Joshi M, Nepple KG, Zakharia Y. Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Des Devel Ther 2017;11:1175-82. [PMID: 28442891 DOI: 10.2147/DDDT.S110209] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
648 Liu K, Zhang X, Xu W, Chen J, Yu J, Gamble JR, McCaughan GW. Targeting the vasculature in hepatocellular carcinoma treatment: Starving vs normalizing blood supply.Clin Transl Gastroenterol. 2017;8:e98. [DOI: 10.1038/ctg.2017.28] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 8.4] [Reference Citation Analysis]
649 Robinson RL, Sharma A, Bai S, Heneidi S, Lee TJ, Kodeboyina SK, Patel N, Sharma S. Comparative STAT3-Regulated Gene Expression Profile in Renal Cell Carcinoma Subtypes. Front Oncol 2019;9:72. [PMID: 30863721 DOI: 10.3389/fonc.2019.00072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
650 Mihaly Z, Sztupinszki Z, Surowiak P, Gyorffy B. A comprehensive overview of targeted therapy in metastatic renal cell carcinoma. Curr Cancer Drug Targets 2012;12:857-72. [PMID: 22515521 DOI: 10.2174/156800912802429265] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
651 Richey SL, Tamboli P, Ng CS, Lin E, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol 2013;36:450-4. [PMID: 22706175 DOI: 10.1097/COC.0b013e3182546a91] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
652 Choueiri TK, Kaelin WG Jr. Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat Med 2020;26:1519-30. [PMID: 33020645 DOI: 10.1038/s41591-020-1093-z] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 19.0] [Reference Citation Analysis]
653 Kim BJ, Kim JH, Kim HS, Zang DY. Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review. Oncotarget 2017;8:13979-85. [PMID: 28103578 DOI: 10.18632/oncotarget.14704] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
654 Gámez-Pozo A, Antón-Aparicio LM, Bayona C, Borrega P, Gallegos Sancho MI, García-Domínguez R, de Portugal T, Ramos-Vázquez M, Pérez-Carrión R, Bolós MV, Madero R, Sánchez-Navarro I, Fresno Vara JA, Espinosa Arranz E. MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Neoplasia 2012;14:1144-52. [PMID: 23308047 DOI: 10.1593/neo.12734] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
655 Wu B, Dong B, Xu Y, Zhang Q, Shen J, Chen H, Xue W. Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. PLoS One 2012;7:e32530. [PMID: 22412884 DOI: 10.1371/journal.pone.0032530] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
656 Alghamdi A, Alkhateeb S, Alghamdi K, Bazarbashi S, Murshid E, Alotaibi M, Abusamra A, Rabah D, Ahmad I, Al-Mansour M, Saadeddin A, Alsharm A. Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma. Urol Ann 2016;8:136-40. [PMID: 27141180 DOI: 10.4103/0974-7796.179239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
657 Ghatalia P, Zibelman M, Geynisman DM, Plimack ER. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma. Curr Treat Options Oncol 2017;18:7. [PMID: 28210995 DOI: 10.1007/s11864-017-0458-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
658 Keisner SV, Shah SR. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 2011;71:443-54. [PMID: 21395357 DOI: 10.2165/11588960-000000000-00000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 37] [Article Influence: 0.7] [Reference Citation Analysis]
659 Harmon CS, DePrimo SE, Figlin RA, Hudes GR, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Williams JA, Eisen T, Motzer RJ. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol 2014;73:151-61. [PMID: 24220935 DOI: 10.1007/s00280-013-2333-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
660 Daste A, Gross-Goupil M, Roca S, Bernhard JC, Ravaud A. Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature. Target Oncol 2014;9:81-4. [PMID: 23283668 DOI: 10.1007/s11523-012-0245-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
661 Schöffski P, Guillem V, Garcia M, Rivera F, Tabernero J, Cullell M, Lopez-Martin JA, Pollard P, Dumez H, del Muro XG, Paz-Ares L. Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma. Mar Drugs 2009;7:57-70. [PMID: 19370171 DOI: 10.3390/md7010057] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
662 Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:4076-81. [PMID: 19636008 DOI: 10.1200/JCO.2008.21.3660] [Cited by in Crossref: 144] [Cited by in F6Publishing: 46] [Article Influence: 11.1] [Reference Citation Analysis]
663 Pagès G. The path to « the Golden Age » for the treatment of metastatic renal cell carcinoma. Oncotarget 2018;9:31564-5. [PMID: 30167076 DOI: 10.18632/oncotarget.25832] [Reference Citation Analysis]
664 Ding Z, German P, Bai S, Reddy AS, Liu XD, Sun M, Zhou L, Chen X, Zhao X, Wu C, Zhang S, Mills GB, Jonasch E. Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein. Cancer Res 2014;74:3127-36. [PMID: 24755468 DOI: 10.1158/0008-5472.CAN-13-3213] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
665 Atkins MB, Choueiri TK, Cho D, Regan M, Signoretti S. Treatment selection for patients with metastatic renal cell carcinoma. Cancer 2009;115:2327-33. [PMID: 19402069 DOI: 10.1002/cncr.24231] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
666 North S, Basappa N, Bjarnason G, Blais N, Canil C, Heng D, Knox J, Reaume N, Ruether D, Soulières D, Zalewski P, Black P, Breau RH, Jewett M, Kapoor A, Lattouf JB, Moore R, Rendon R, Todd G, Pituskin E, Gedye C, Wood L. Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013. Can Urol Assoc J 2013;7:238-43. [PMID: 24032057 DOI: 10.5489/cuaj.536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
667 Zibelman M, Plimack ER. Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old? Ann Transl Med 2019;7:S95. [PMID: 31576303 DOI: 10.21037/atm.2019.04.57] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
668 Thakur A, Jain SK. Kidney Cancer: Current Progress in Treatment. World J Oncol 2011;2:158-65. [PMID: 29147242 DOI: 10.4021/wjon345w] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
669 Meric JB, Billemont B, Rixe O. [New therapeutics strategies in renal cell carcinoma]. Bull Cancer 2010;97:53-63. [PMID: 20418204 DOI: 10.1684/bdc.2010.1070] [Reference Citation Analysis]
670 Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, Van Cann T, Willems L, Body JJ, Berkers J, Van Poppel H, Lerut E, Debruyne P, Paridaens R, Schöffski P. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer 2012;107:1665-71. [PMID: 23132391 DOI: 10.1038/bjc.2012.385] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 8.0] [Reference Citation Analysis]
671 Osanto S, van der Hulle T. Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience. Ther Adv Urol 2018;10:109-23. [PMID: 29662541 DOI: 10.1177/1756287217748867] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
672 Cai J, Han S, Qing R, Liao D, Law B, Boulton ME. In pursuit of new anti-angiogenic therapies for cancer treatment. Front Biosci (Landmark Ed) 2011;16:803-14. [PMID: 21196204 DOI: 10.2741/3721] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
673 Motzer RJ, Hudes G, Wilding G, Schwartz LH, Hariharan S, Kempin S, Fayyad R, Figlin RA. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2009;7:28-33. [PMID: 19213665 DOI: 10.3816/CGC.2009.n.005] [Cited by in Crossref: 54] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
674 Nishimura T, Furihata M, Kubo H, Tani M, Agawa S, Setoyama R, Toyoda T. Intracranial hemorrhage in patients treated with bevacizumab: Report of two cases. World J Gastroenterol 2011; 17(39): 4440-4444 [PMID: 22110272 DOI: 10.3748/wjg.v17.i39.4440] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
675 Doehn C, Grünwald V, Steiner T, Follmann M, Rexer H, Krege S. The Diagnosis, Treatment, and Follow-up of Renal Cell Carcinoma. Dtsch Arztebl Int 2016;113:590-6. [PMID: 27658472 DOI: 10.3238/arztebl.2016.0590] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
676 Ciric E, Sersa G. Radiotherapy in combination with vascular-targeted therapies. Radiol Oncol 2010;44:67-78. [PMID: 22933894 DOI: 10.2478/v10019-010-0025-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
677 Gimenez SE, Secasan C, Raman JD. Prognostic markers and targeted therapies for renal cell carcinoma. Future Oncol 2009;5:197-205. [PMID: 19284378 DOI: 10.2217/14796694.5.2.197] [Reference Citation Analysis]
678 Wu H, Liu M, He Y, Meng G, Guo W, Guo Q. Expression of BAG1 is associated with prognosis in kidney renal clear cell carcinoma based on bioinformatics. BMC Cancer 2021;21:160. [PMID: 33581726 DOI: 10.1186/s12885-021-07874-w] [Reference Citation Analysis]
679 Hirai F, Seto T, Inamasu E, Shimokawa M, Toyokawa G, Yoshida T, Nosaki K, Takenaka T, Yamaguchi M, Takenoyama M, Ichinose Y. Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer. Oncol Lett 2015;9:2577-82. [PMID: 26137109 DOI: 10.3892/ol.2015.3086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
680 Rappold PM, Silagy AW, Kotecha RR, Hakimi AA. Immune checkpoint blockade in renal cell carcinoma. J Surg Oncol 2021;123:739-50. [PMID: 33595892 DOI: 10.1002/jso.26339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
681 Kitada S, Yamada S, Kuma A, Ouchi S, Tasaki T, Nabeshima A, Noguchi H, Wang KY, Shimajiri S, Nakano R, Izumi H, Kohno K, Matsumoto T, Sasaguri Y. Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas. Br J Cancer 2013;109:472-81. [PMID: 23799843 DOI: 10.1038/bjc.2013.331] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
682 Chandra A, Rick J, Yagnik G, Aghi MK. Autophagy as a mechanism for anti-angiogenic therapy resistance. Semin Cancer Biol 2020;66:75-88. [PMID: 31472232 DOI: 10.1016/j.semcancer.2019.08.031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
683 Molina AM, Nanus DM. Recent advances in the management of renal cell carcinoma. F1000Res 2016;5:F1000 Faculty Rev-391. [PMID: 27019698 DOI: 10.12688/f1000research.7935.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
684 Tsukada Y, Nakamura F, Iwamoto M, Terahara A, Higashi T. Patterns of prescribing radiotherapy and bevacizumab in nationwide practice - analysis of 101 designated cancer care hospitals in Japan. J Radiat Res 2016;57:157-63. [PMID: 26661853 DOI: 10.1093/jrr/rrv080] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
685 Xu W, Atkins MB, McDermott DF. Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol 2020;17:137-50. [PMID: 32020040 DOI: 10.1038/s41585-020-0282-3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 49] [Article Influence: 20.0] [Reference Citation Analysis]
686 Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ 2014;349:g4797. [PMID: 25385470 DOI: 10.1136/bmj.g4797] [Cited by in Crossref: 223] [Cited by in F6Publishing: 229] [Article Influence: 27.9] [Reference Citation Analysis]
687 Hannouf MB, Winquist E, Mahmud SM, Brackstone M, Sarma S, Rodrigues G, Rogan PK, Hoch JS, Zaric GS. The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study. Pharmacoecon Open 2018;2:255-70. [PMID: 29623630 DOI: 10.1007/s41669-017-0051-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
688 Banyra O, Tarchynets M, Shulyak A. Renal cell carcinoma: how to hit the targets? Cent European J Urol 2014;66:394-404. [PMID: 24757527 DOI: 10.5173/ceju.2013.04.art2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
689 Khattak M, Larkin J. Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance. World J Urol 2014;32:19-29. [PMID: 23297098 DOI: 10.1007/s00345-012-1013-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
690 Yoshimura S, Tsunoda T, Osawa R, Harada M, Watanabe T, Hikichi T, Katsuda M, Miyazawa M, Tani M, Iwahashi M, Takeda K, Katagiri T, Nakamura Y, Yamaue H. Identification of an HLA-A2-restricted epitope peptide derived from hypoxia-inducible protein 2 (HIG2). PLoS One 2014;9:e85267. [PMID: 24416375 DOI: 10.1371/journal.pone.0085267] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
691 Tracz AF, Szczylik C, Porta C, Czarnecka AM. Insulin-like growth factor-1 signaling in renal cell carcinoma. BMC Cancer 2016;16:453. [PMID: 27405474 DOI: 10.1186/s12885-016-2437-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
692 Villaruz LC, Kalyan A, Zarour H, Socinski MA. Immunotherapy in lung cancer. Transl Lung Cancer Res 2014;3:2-14. [PMID: 25806276 DOI: 10.3978/j.issn.2218-6751.2013.10.13] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
693 Herrmann E, Weishaupt C, Pöppelmann B, Hillgruber C, Pühse G, Krabbe LM, Feld M, Steinhoff M, Goerge T. New tools for assessing the individual risk of metastasis in renal cell carcinoma. Clin Exp Metastasis 2013;30:215-24. [PMID: 22915161 DOI: 10.1007/s10585-012-9529-6] [Cited by in Crossref: 4] [Cited by i